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ABSTRACT 
 
Mezher Adli 
Investigating the role of IKK (epsilon) in cancer-associated NF-B activity 
(Under the direction of Prof. Albert S. Baldwin) 
 
Nuclear Factor 3B (NF-3B) has been studied extensively as an inducible 
transcriptional regulator of the immune and inflammatory responses. NF-3B activation 
downstream of LPS or cytokine stimulation is controlled by the IB kinase complex 
which contains IKK and IKK and NEMO. Significantly, the constitutive activity of 
NF-3B has been implicated as an important aspect of many cancer cells but mechanisms 
associated with this activity are poorly understood. An inducible kinase, IKK-i / IKK,
related to the catalytic forms of the I3B kinase, has been studied as an anti-viral, innate 
immune regulator through its ability to control the activity of the transcription factors 
IRF-3 and IRF-7. Here, we demonstrate that IKK-i / IKK is expressed in a number of 
cancer cells and is involved in regulating NF-3B activity through its ability to control 
basal/constitutive, but not cytokine induced, p65/RelA phosphorylation at ser536, a 
modification proposed to contribute to the transactivation function of NF-3B. 
Knockdown of IKK-i / IKK or expression of a S536A mutant form of p65 suppresses 
HeLa cell proliferation. The data indicate a role for IKK-i / IKK in controlling
iii
proliferation of certain cancer cells through regulation of constitutive NF-3B activity. 
Moreover, microarray analysis of gene expression profiles in cancer cells with RNAi 
mediated IKK knock-down demonstrated a number of genes that are highly regulated by 
IKK. Among these genes, we were particularly interested in the Bcl-3 oncogene. After 
the observation that Bcl-3 gene expression is significantly reduced in microarray data 
following IKK knock-down, we further confirmed and validated the microarray data by 
showing that overexpression of IKK> significantly upregulates Bcl-3 gene expression and 
that IKK knock down downregulates it. Moreover, our data suggest that Bcl-3 gene 
expression is defective in IKK knock-out MEF cells both at the protein level and at the 
message level. Promoter studies indicate that IKK regulates Bcl-3 gene expression 
through NF-B. We have also observed a significant correlation between IKK>
expression and Bcl-3 expression in HCC tumors compared to adjacent tissue. My 
hypothesis is that IKK regulation in cancer promotes oncogenic potential partly through 
the induced regulation of Bcl-3.  
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INTRODUCTION 
 
The Nuclear Factor kappa B (NF-B)
Since its initial discovery more than 20 years ago, the transcription factor Nuclear 
Factor-kappaB (NF-B) is still at the center of intensive research because if its crucial 
role in inflammation, immunity, controlling cell death and proliferation, which are 
hallmarks of many challenging human diseases such as cancer [1, 2]. Cells regulate 
immediate and long-lived cellular responses to environmental stimuli via activation of 
transcription factors. NF-B is an evolutionarily conserved inducible transcription factor 
that responds to a diverse set of environmental changes. Among biological systems, NF-
B plays an essential role in the immune system by regulating the expression of 
cytokines, growth factors, and effector enzymes in response to ligation of many receptors 
involved in immunity, including T-cell receptors (TCRs), B-cell receptors (BCRs), 
TNFR, BAFFR, LTR and the Toll/IL-1R family [3]. Furthermore, NF-B also regulates 
the expression of many genes outside of the immune system such as the development and 
physiology of the mammary gland, bone, skin and other important biological systems 
such as the nervous system. Based on strong functional implications in varied essential 
biological roles, understanding how the transcriptional potential, activity, and selectivity 
of NF-B are regulated is therefore the focus of extensive research. 
2NF-B family proteins
Mammalian NF-B is a family of 5 proteins composed of NF-B1 (p50/p105), 
NF-B2 (p52/p100) and 3 Rel family proteins; c-Rel, RelB, RelA (p65). These proteins 
exist as homo- or heterodimers bound by inhibitory B (IB) proteins within the 
cytoplasm of unstimulated cells [3]. NF-B proteins share the highly conserved Rel 
Homology Domain (RHD) located towards the N terminus of the protein that is 
responsible for dimerization, interaction with IB proteins and DNA binding. In contrast 
to the Rel subfamily proteins, which contain C-terminal transactivation domain, the 
unprocessed p105 and p100 NF-B subfamily proteins have ankyrin repeats in their long 
C termini that act as intramolecular inhibitory B protein (IB) domains [4]. Upon 
activation, NF-B1 and NF-B2 proteins are processed, partially degraded on their 
ankyrin repeats in their C-terminal domains to generate p50 or p52 which then dimerize 
with the Rel proteins to act as transcriptional activators [2, 3]. In unstimulated cells, NF-
B transcription factor is tightly regulated by one of the several inhibitors of NF-B
called inhibitory B proteins (IB). 
 
Mammalian Inhibitory kappa B proteins (IB)
The activity of NF-B is primarily regulated by interaction with inhibitory IB
proteins. There are several IB proteins, which have different affinities for individual 
Rel/NF-B complexes. They are regulated slightly differently, and are expressed in a 
tissue-specific manner. The inhibitory kappa B family of proteins include IB, IB,
IB, IB, IB	, Bcl-3 and the C terminal precursors of p105 (NF-B1) and p100 (NF-
3B2) [3, 4]. The interaction with IB proteins (but Bcl-3) blocks the ability of NF-B to 
translocate to the nucleus and bind to DNA and therefore results in the NF-B complex 
being primarily in the cytoplasm due to masking of nuclear localization signal on NF-B
dimers and a strong nuclear export signal in IB. A large number of intra and extra-
cellular stimuli, including ROS, cytokines, PMA, bacterial LPS, viral infection, and T 
and B cell activation, lead to NF-B activation which involves phosphorylation and 
subsequent ubiquitination (generally by a complex called beta-TrCP) and degradation of 
IB proteins by the 26S proteosome complex [5, 6]. The released NF-B transcription 
factor with unmasked nuclear localization signal then translocates to the nucleus, binds to 
DNA and regulates the expression of target genes [3]. As described below, IB
phosphorylation by the high molecular weight IB kinase (IKK) complex (approximately 
700 kDa) is one of the critical regulatory steps in the NF-B activation [7].  
 
IB kinase (IKK) complex
A large kinase complex responsible for IB phosphorylation and subsequent 
degradation was initially partially identified from unstimulated HeLa cells and was later 
found to be activated in cells treated with TNF [8, 9]. Subsequently several groups 
identified two highly related kinases named  IKK (IKK1) and IKK (IKK2) as the main 
kinase components of this kinase complex [10-12]. Both of these kinases have been 
shown to have specificity for serine residues in the destruction box of IB protein and 
can directly phosphorylate S32 and S36 residues [10]. In addition to IKK and IKK, a
non-catalytic, structural component called IKK (NEMO) was also identified to be an 
4essential component of the IKK complex [13-15]. Please refer to [10] for more extensive 
and detailed review about the IKK complex. 
 
Much of the information about the physiological roles of each of the IKKs comes 
from gene targeting studies. Extensive research has demonstrated that IKK, IKK and 
NEMO have distinct roles in terms of regulating differential physiological functions [3, 
7]. IKK and NEMO knock out mice displayed similar phenotypes of embryonic 
lethality with severe liver apoptosis. Mouse embryonic fibroblast (MEF) cells that were 
isolated from IKK deficient embryos showed a marked reduction in tumor necrosis 
factor-alpha (TNF) and interleukin-1alpha (IL-1)-induced NF-B activity and 
enhanced apoptosis in response to TNF [16, 17]. In contrast, IKK deficient mice have 
a wide range of morphogenesis and developmental defects. Although loss of IKK did 
not seem to be critical for IKK activation and IB phosphorylation, IKK-deficient 
mouse embryonic fibroblast (MEF) cells have diminished NF-B activation induced by 
TNF and IL-1 [16, 18]. Therefore, it was claimed that IKK is essential for NF-B
activation in the limb and skin during embryogenesis, however loss of IKK does not 
effect cytokine induced  NF-B activation in fibroblasts and thymocytes [19]. 
 
In the light of these genetic studies and additional biochemical studies, it was 
suggested that IKK and IKK have distinct functional roles [20]. Genetic and 
mutational analysis, highlighted that IKK but not IKK is the primary component of 
NF-B dependent proinflammatory signal transduction [21]. On the other hand, IKK is 
believed to be essential in the so-called non-canonical NF-B activation pathway by 
5regulating p100 precursor processing and NF-B dependent developmental processes [7]. 
Recently some additional distinct nuclear roles of IKK have been discovered. We and 
others have demonstrated that IKK has an important nuclear function by regulating the 
control of target genes at the level of histone phosphorylation [22, 23]. Although the 
initial knock-out study for IKK suggested its role on canonical NF-B signaling 
pathway in MEFs [16], this function of IKK is poorly understood.   
 
NEMO (IKK) is the other important structural component of IKK complex. 
Besides being required for the normal function of the IKK complex, NEMO has been 
demonstrated to have an essential nuclear function in the activation of IKK signaling in 
response to DNA damage. Genotoxic stresses, which are caused by irradiation or 
topoisomerase I- or II-inhibiting drugs and other DNA damaging agents, are well 
documented to activate cytoplasmic IKK and NF-B. The signals that are induced upon 
generation of DNA double-strand breaks by these treatments originate from the nucleus 
and have to be processed by the cytoplasmic IKK complex [7]. The most important 
sensor for DNA double-strand breaks is the nuclear kinase ATM, which is rapidly 
activated by genotoxic stress and activates IKK and NF-B [24]. Subsequent research has 
demonstrated that genotoxic stress causes ATM directed phosphorylation of NEMO and 
subsequent modifications with small ubiquitin-like modifier (SUMO-1), and 
ubiquitination. It is believed that ubiquitination of NEMO dictates its translocation to 
cytoplasm where it activates the classical IKK complex and hence NF-B activation [25].  
 
Other IKK related kinases: IKK and TBK1
6Based on a number of observations, it was assumed that virtually all inducers of 
NF-3B lead to the activation of a single classical IKKM/I/N complex. However, recent 
studies demonstrated the existence of distinct IKK complexes that do not contain IKKM,
I, or N [26].  One of these complexes was described as a PMA-inducible I3B kinase 
complex, with a critical component being an IKK-related kinase designated IKK>Q [27], 
which is identical to a kinase named IKK-i identified via its induction downstream of 
LPS-induced signaling [19]. IKK> in turn is closely related to another recently discovered 
IKK-related kinase designated as TBK1 (TANK-Binding Kinase 1) [28] or NAK (NF-3B
Activating Kinase) [29].  TBK1, which is highly homologous to IKK>, binds to TANK 
and TRAF and may form an alternative IKK complex consisting of IKK> and TBK1 [28]. 
There is significant sequence similarity between IKK and TBK1 (~66 %) and they share 
a significant similarity in their kinase domains with IKK and IKK (Figure A). 
 
IKK> and TBK1 are enzymatically distinct from the homologous enzymes IKKM
and IKKI [30] and have been shown to play important roles in the innate immune 
response. These kinases function as critical components of the interferon regulatory 
factor 3 (IRF3) and IRF7 signaling pathways involved in responses to viral infection or 
dsRNA treatment [31, 32]. Recent studies demonstrated that embryonic fibroblasts 
(MEFs) derived from TBK1-deficient (TBK1-/-) mice show impaired production of NF-
3B- [33] as well as IRF3-dependent gene expression [31]. It has also been shown that 
IFN-I and IFN-inducible gene expression is defective in TBK1 knock-out cells in 
response to lipopolysaccharide (LPS), poly (I:C) or viral infection [34-36]. 
The relationships of IKK> and TBK1 with NF-3B activation remain enigmatic.  
7Although recent studies defined their roles in IRF3 and IRF7 transcriptional activation 
[31, 32] and suggested their involvement in NF-3B activation [28-30, 33, 37, 38], the 
exact molecular mechanism of NF-3B activation by these kinases is not clearly 
understood. One report [39] indicated that IKK> plays a key role in integrating signals 
induced by pro-inflammatory stimuli by activating C/EBP whose expression is regulated 
by NF-3B. There is a recent report suggesting that IKK> and TBK1 are among the 
kinases that mediate inducible phosphorylation of p65 at Ser-536 [40], an event proposed 
to stimulate inherent p65 transactivation function [41]. In this model, TBK1 and IKK>
would control NF-3B at a level distinct from the traditional IKK-mediated control of I3B
degradation. How IKK regulates the expression of its target genes is not clearly 
understood, however our results suggest that p65 phosphorylation at ser 536 position is 
an important step. In support of our data, IKK has recently been shown to interact with 
p52 and promote transactivation via p65 activation [42]. We cannot rule out the 
possibility that IKK has other roles in other NF-B activating pathways as the 
significant of IKK involvement is recently being appreciated. One study, for example, 
demonstrated that TBK1 and IKK directly phosphorylate the C-terminal domain of cRel 
in vitro and in vivo and regulate nuclear accumulation of cRel, independently of the 
classical IkappaB/IKK pathway [32]. While this work was in preparation, Boehm at al., 
published a paper in the most recent issue of Cell that clearly identified IKK as a Breast 
Cancer Oncogene by using Integrative Genomic Approaches such as overexpression and 
siRNA screening as well as comparative genomics analysis [43]. In line with our 
published studies, they also showed that in many breast cancer cell lines as well as breast 
cancer carcinomas, IKK is overexpressed and this overexpression is driving NF-B
8activity which provide prosurvival signal in cancer setting.  
 
In addition to their well established roles in IRF3 and IRF7 activation during 
innate immunity, recent studies by several groups including ours [43-46] implicated the 
involvement of IKK in cancer signaling mechanism. Interestingly TBK1 has also been 
implicated in tumor cell survival [47]. Although research from several groups recently 
appreciated the implication of IKK and TBK1 cancer progression and tumor cell 
survival, the molecular mechanism of IKK and TBK1 induced cancer signaling 
mechanism and downstream target genes remain to be identified.  
9IKK
IKK
IKK
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Kinase domain                                         Helix Loop Helix
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Figure A: Schematic outline of functional domains and sequence similarities in 
IKK, IKK, IKK and TBK1. Numbers represent percent sequence similarity 
between each of kinases. 
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Overview of the NF-B activation pathways
NF-B activation downstream of the classical IKK kinase complex in response to 
cytokines and other well studied NF-B inducers is relatively well established. The 
signaling mechanism of positive and negative regulation of NF-B upon stimulus 
induction has been demonstrated to be either canonical (classical) or non-canonical (non-
classical) signaling pathway (Figure 1.2). In the canonical NF-B activation pathway, 
NF-B dimers such as p50/RelA are maintained in the cytoplasm by interaction with an 
independent IB molecule (often IBa). In many cases, the binding of a ligand to a cell 
surface receptor (e.g., tumor necrosis factor-receptor (TNF-R) or a Toll-like receptor) 
activates the IKK complex (IKK//) which leads to phosphorylation and subsequent 
degradation of the inhibitory subunit (IB). Released NF-B dimers then translocate to 
the nucleus to regulate the expression of  target genes [1]. In the non-canonical pathway, 
certain ligands (e.g., Lymphotoxin  (LT), B-cell activating factor (BAFF) and CD40) 
binding to their cognate cell surface receptors leads to activation of the NF-B-inducing 
kinase NIK, which phosphorylates and activates an IKK complex, which in turn, 
phosphorylates two serine residues adjacent to the ankyrin repeat C-terminal IB domain 
of p100, leading to its partial proteolysis and liberation of the p52/RelB complex [3] 
(Figure B) 
 
In addition to the well established stimulus-induced positive and negative 
regulation of NF-B, there are other NF-B activating pathways involved especially in 
constitutive or basal NF-B activity. Research from our lab and other groups have 
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suggested IKK as an important kinase implicated in basal or constitutive activation of 
NF-B in cancer-associated signaling mechanisms [44, 45]. Evidence so far suggests that 
an IKK- and IKK-independent phosphorylation of p65 at the Ser 536 position is 
critical for this activity. Cancer associated, IKK-induced basal or constitutive NF-B
activity is critical for survival and proliferation of tested cancer cell lines. Whether this is 
a general mechanism of NF-B activation in cancer or only applied to certain cancer cell 
lines is yet to be understood. Interestingly, IKK is not involved in cytokine induced NF-
B activation suggesting non-redundant roles for IKK/ and IKK [44]. Research from 
our lab and other groups indicated that Bcl-3, as a NF-B target gene, is potentially the 
mechanistic link between constitutive NF-B activity and cell survival and cell 
proliferation. 
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Figure B: Classical and non-classical, alternative pathways of NF-B activation. A 
model depicting three different signaling pathways to NF-B. Classical pathway is 
mediated by activation of IKK by inputs such as TNF, TCR, IL-1, LPS and many 
others leading to IKK dependent phosphorylation and subsequent degradation of IB. 
The alternative pathway involves NIK dependent activation of IKK which leads to 
phosphorylation of processing p100, generating p52:RelB heterodimers. Inputs that 
activate alternative signaling pathway include LT, BAFF, and CD40. In constitutive 
NFB activation pathway, without any outside stimuli IKK and potentially other 
unknown kinases induces p65 phosphorylation and hence NF-B activity independent of 
classical IKK complex. 
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Bcl-3; not just another inhibitory protein
Bcl-3 is a member of ankyrin-repeat-containing IB family of NF-B inhibitors 
[3]. It was identified 20 years ago by molecular cloning of the breakpoint of the t(14;19) 
chromosomal translocation from a subset of human B-cell chronic lymphocytic 
leukemias [48]. Translocation at this point leads to Bcl-3 overexpression that results in 
dysregulation of mostly unexplored downstream target genes that are involved in 
differentiation, cell survival and apoptosis [49]. Although Bcl-3 shares significant 
structural features with IB proteins [50, 51], Bcl-3 contains two transactivating domains 
and can function as a transcriptional activator or repressor by forming heterocomplexes 
with the NF-B p50 or p52 subunits in a phosphorylation dependent manner [51-55].  
Although the molecular mechanism of Bcl-3 dual function is poorly understood, some 
observations explain how Bcl-3 may act as both transcriptional activator as well as 
repressor. It was suggested that Bcl-3 can potentially act as a transcriptional activator by 
removing repressor p50 homodimers from the B sites [51] and also by acting as a 
bridging factor between NFB and other coactivators such as  JAB1, Bard1 and Tip60 
[56]. Similarly, upon IL-1 stimulation, Bcl-3 recruits Tip60 acetyltransferase containing 
activator complex to the promoter region of a specific subset of NF-B dependent genes 
[57]. Moreover, Bcl-3 was also suggested to function as a coactivator itself by regulating  
the expression of subset of NF-B dependent genes in response to TNF [58]. In contrast 
to its transactivator potential Bcl-3 has also been suggested to act as a transcriptional 
repressor. It has been demonstrated that Bcl-3 can physically interact with HDAC-1, -2 
and -3 which are involved gene repression [59]. Another study also demonstrated that 
Bcl-3 inhibits LPS-induced inflammatory responses in macrophages by recruiting 
14
HDAC-1 [60]. Although the opposite dual function of Bcl-3 is poorly understood, one 
explanation may come from the posttranslational modifications on Bcl-3 or Bcl-3 
interacting proteins. Bcl-3 has two residues within its C-terminal domain that are 
phosphorylated by GSK3 kinase which mediates its interaction with HDAC1 and induce 
its degradation through the proteosome pathway [59]. Although protein phosphorylation 
was suggested to be the key mechanism for regulation of Bcl-3 activity [61], other 
posttranslational modifications such as ubiquitination was recently demonstrated to be 
critical for Bcl-3 nuclear translocation [62]. For instance, It was clearly demonstrated that 
TPA or UV light triggers the translocation of tumor suppressor CYLD from the 
cytoplasm to the perinuclear region, where CYLD binds and deubiquitinates Bcl-3, 
thereby preventing nuclear accumulation of Bcl-3 and p50/Bcl-3- or p52/Bcl-3-dependent 
gene expression and subsequent cell proliferation [62]. 
 
Bcl-3 has been implicated in many crucial physiological events such as cell 
proliferation, immune, inflammation and cancer progression. The results from Bcl-3 
knock-out mice revealed critical roles for Bcl-3 in antigen-specific priming of T and B 
cells [63]. Bcl-3 deficient mice are also impaired in germinal center reactions and T cell-
dependent antibody responses to influenza virus that may underlie the immunologic 
defects [64]. It was shown that Bcl-3 associates with NF-B p50 or p52 subunits and 
strongly enhances cell proliferation and oncogenesis through activation of the cyclin D1 
promoter [23, 65]. In line with these observations, EµBcl-3 transgenic mice develop 
lymphoproliferative disorders such as; Lymphadenopathy, splenomegaly, and altered 
immunoglobulin production [66]. Furthermore,  although the mechanism is poorly 
15
understood, Bcl-3 was shown to directly transform cells [59].  Research  has also 
demonstrated that Bcl-3 exerts anti-apoptotic activity in B and T lymphocytes [67, 68] 
and controls the death of activated T cells [69]. Despite its well established role in cell 
proliferation and apoptosis, the signaling pathways and upstream key effecters that 
activate Bcl-3 gene expression are poorly understood. 
 
CHAPTER I 
 
IKK-i / IKK (epsilon) controls constitutive, cancer cell-associated NF-kappaB 
activity via regulation of Ser-536 p65/RelA phosphorylation 
 
This Chapter was originally published in Journal of Biological Chemistry (2006) 
Sep 15;281(37):26976-84. 
Permission for reprinting has been granted. 
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Abstract
Nuclear factor kappaB (NF-kappaB) has been studied extensively as an inducible 
transcriptional regulator of the immune and inflammatory response. NF-kappaB activation 
downstream of lipopolysaccharide or cytokine stimulation is controlled by the IkappaB 
kinase complex, which contains IKKalpha and IKKbeta. Significantly, the constitutive 
activity of NF-kappaB has been implicated as an important aspect of many cancer cells, 
but mechanisms associated with this activity are poorly understood. An inducible kinase, 
IKK-i / IKK epsilon, related to the catalytic forms of the IkappaB kinase, has been studied 
as an anti-viral, innate immune regulator through its ability to control the activity of the 
transcription factors IRF-3 and IRF-7. Here, we demonstrate that IKK-i / IKK epsilon is 
expressed in a number of cancer cells and is involved in regulating NF-kappaB activity 
through its ability to control basal/constitutive, but not cytokine-induced, p65/RelA 
phosphorylation at Ser-536, a modification proposed to contribute to the transactivation 
function of NF-kappaB. Knockdown of IKK-i / IKK epsilon or expression of a S536A 
mutant form of p65 suppresses HeLa cell proliferation. The data indicate a role for IKK-i / 
IKK epsilon in controlling proliferation of certain cancer cells through regulation of 
constitutive NF-kappaB activity. 
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Introduction
The transcription factor Nuclear Factor-3B (NF-3B) plays a pivotal role in 
controlling the expression of a diverse set of genes that contribute to a variety of biological 
functions including cell survival, cell proliferation, and immune and inflammatory 
responses [3].  The classic form of NF-3B is composed of a heterodimers of the p50 and 
p65 subunits which is preferentially localized in the cytoplasm as an inactive complex 
with inhibitor proteins of the I3B family.  Following exposure of cells to a variety of 
stimuli, including inflammatory cytokines and LPS, I3Bs are phosphorylated by the 
IKKM/I complex, polyubiquitinated and subsequently degraded by the 26S proteosome 
complex [3, 70].  Released NF-3B complexes then accumulate in the nucleus, where they 
transcriptionally regulate the expression of genes involved in the immune and 
inflammatory responses [3].  
 
Based on a number of observations, it was assumed that virtually all inducers of 
NF-3B lead to the activation of a single classical IKKM/I/N complex.  However, recent 
studies demonstrated the existence of distinct IKK complexes that do not contain IKKM, I,
or N [26].  One of these complexes was described as a PMA-inducible I3B kinase complex, 
with a critical component being an IKK-related kinase designated IKK>Q [27], which is 
identical to a kinase named IKK-i identified via its induction downstream of LPS-induced 
signaling [19].  IKK> in turn is closely related to another recently discovered IKK-related 
kinase designated as TBK1 (TANK-Binding Kinase 1) [28] or NAK (NF-3B Activating 
Kinase) [29].  TBK1, which is highly homologous to IKK>, binds to TANK and TRAF 
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and may form an alternative IKK complex consisting of IKK> and TBK1 [28].  
 
IKK> and TBK1 are enzymatically distinct from the homologous enzymes IKKM
and IKKI [30] and have been shown to play important roles in the innate immune 
response. These kinases function as critical components of the interferon regulatory factor 
3 (IRF3) and IRF7 signaling pathways involved in responses to viral infection or dsRNA 
treatment [31, 32].  Recent studies demonstrated that embryonic fibroblasts (MEFs) 
derived from TBK1-deficient (TBK1-/-) mice show impaired production of NF-3B- [33] 
as well as IRF3-dependent gene expression [31].  It has also been shown that IFN-I and 
IFN-inducible gene expression is defective in TBK1 knock-out cells in response to 
lipopolysaccharide (LPS), poly (I:C) or viral infection [34-36]. 
 
The relationships of IKK> and TBK1 with NF-B activation remain enigmatic.  
Although recent studies defined their roles in IRF3 and IRF7 transcriptional activation [31, 
32] and suggested their involvement in NF-B activation [28-30, 33, 37, 38], the exact 
molecular mechanism of NF-B activation by these kinases is not clearly understood. One 
report (19) indicated that IKK> plays a key role integrating signals induced by pro-
inflammatory stimuli by activating C/EBP whose expression is regulated by NF-3B.  
There is a recent report suggesting that IKK> and TBK1 are among the kinases that 
mediate inducible phosphorylation of p65 at Ser-536 [40], an event proposed to stimulate 
inherent p65 transactivation function [41].  In this model, TBK1 and IKK> would control 
NF-3B at a level distinct from the traditional IKK-mediated control of IB degradation.  
Here, we show that IKK is expressed in a variety of cancer cell lines. Based on 
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this, we have investigated a role for IKK> as related to constitutive, cancer-associated NF-
B activity. Our experiments reveal an important role for IKK in controlling the 
activation of Ser-536 phosphorylation of the RelA/p65 subunit and functional NF-B
activity in several cancer cell lines and in 293T cells. 
 
Results
IKK is expressed in a number of cancer cells and in SV40 large T-immortalized 
293 cells. In order to address a potential role for IKK in controlling NF-B activity, we 
explored the expression of IKK in a variety of cell lines. Immunoblotting of extracts of 
several cancer cell lines revealed constitutive expression of IKK in breast cancer cell 
lines MDA MB 468, SK BR3, Sum 226, and MCF7; HeLa cells; PC3 and LNCaP prostate 
cancer cells; and  293T embryonic kidney cells (Fig. 1). As a marker for endogenous NF-
B activity, we immunoblotted the extracts from these cells with an antibody which 
recognizes only the RelA/p65 subunit phosphorylated at Ser-536. These data revealed a 
correlation between IKK expression and phosphorylated Ser-536 RelA/p65 in most of the 
cells analyzed. Notably, TBK1 was expressed in these cells but did not consistently 
correlate with RelA/p65 Ser-536 phosphorylation. The data also reveal that IKK, while 
considered an inducible kinase, is found to be constitutively expressed at significant levels 
in most of the cell lines investigated.  
IKK or TBK1 activates an NF-*B-dependent reporter in a kinase-dependent 
manner. To investigate a potential role for IKK> and TBK1 in NF-3B regulation, 
experiments were initiated to analyze their potential involvement in controlling NF-3B-
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dependent promoters. Based on the results from Figure 1, we focused these experiments 
on HEK 293T cells since IKK is expressed and is potentially active in these cells.  Both 
IKK> and TBK1, but not their kinase mutant forms, activated the 3X-3B and IFN-I
luciferase promoter constructs (Figs. 2A and 2B). Unlike the 3X-3B promoter, the IFN-I
promoter is considered a complex promoter regulated by coordinate actions of NF-3B and 
other transcription factors, therefore it is not considered to be regulated exclusively by NF-
3B.  These results are similar to those of Shimada et al [19].  Interestingly, in all of the 
assays performed, TBK1 was observed to be a better activator of the reporters (Figs. 2A 
and 2B).  Analysis of the effects of different concentrations of IKK> on activation of the 
3X-3B luciferase reporter showed that fold induction of luciferase activity is proportional 
to the IKK> plasmid concentration, whereas there was no significant induction with the 
vector control or with the kinase mutant (KM) form of IKK> (Fig. 2C).  
 
IKK expression induces NF-*B DNA binding activity. We next investigated 
whether IKK> expression can induce NF-3B binding to a consensus DNA target sequence.  
Flag-tagged IKK> was transiently expressed in HEK 293T cells for approximately 48 hrs 
and nuclear extracts were prepared for Electrophoretic Mobility Shift Assays (EMSAs).  
As shown in Fig. 3A, IKK> effectively induces DNA binding activity of NF-3B.  TNF-M is 
included in this experiment for comparison purposes. It should be noted that there is basal 
NF-3B DNA binding activity in the VC lane (lane 1), which is better visualized given 
longer exposure times. TNF-M stimulation of IKK>-overexpressing cells led to more DNA 
binding activity but this increase appears to be an additive effect of TNF-M and IKK>
rather than a synergistic effect. Western blot analysis of cytoplasmic extracts shown in the 
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lower panel, demonstrates expression levels of IKK>. We next aimed to investigate the 
nature of the major NF-3B subunits in this bound complex by gel shift assay. For this 
purpose each of the reactions used in Fig. 3A has been incubated with the indicated 
antibody and electrophoresed on a separate gel (Fig. 3B). The number on the top of the 
figure indicates the lane numbers (1-4) from the reactions used in Fig. 3A.   In the lanes 
where an NF-3B complex is detected (2, 3, 4), there is a positive response with the p65 
and p50 antibodies. Therefore, we concluded that the complex that bound to this 
consensus binding site is composed predominantly of p65/p50 heterodimers (Fig. 3B). It 
should be noted that a single nucleotide change can lead to binding of different NF-B
subunits [58, 71] therefore we can not exclude the possibility that other subunits might 
also be activated and bind to slightly different NF-3B binding sites. TBK1 expression 
effects on DNA binding activity of NF-3B yielded very similar results (data not shown).  
 
IKK and TBK1 expression leads to phosphorylation of endogenous p65 at Ser-
536. Recent studies have shown that post-translational modification of NF-3B subunits, 
such as p65, contribute significantly to NF-3B transactivation potential (reviewed in [3]).  
Phosphorylation of p65 at Ser-536 is proposed to be a key modification that potentiates 
p65 transactivation function, hence NF-3B activation [41, 72].  We next tested if IKK> and 
TBK1 affect p65 phosphorylation.  We tested whether ectopically expressed IKK> leads to 
phosphorylation of endogenous p65 at Ser-536. Expression of GFP-IKK> leads to a 
significantly higher level of p65 phosphorylation at the Ser-536 position (indicated as P-
p65 (Ser-536)) (Fig. 4A).  Utilization of GFP-tagged IKK> expression vector allows for 
distinguishing between ectopically expressed IKK> (GFP-IKK>) and  endogenous IKK>.
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This experiment reveals that IKK> induces higher levels of endogenous IKK (Fig. 4A), 
which has been proposed to be regulated by NF-3B [73]. This observation suggests that 
ectopically expressed IKK> is able not only to induce phosphorylation of endogenous p65 
but also to induce NF-3B dependent gene expression.  Next we examined if TBK1, an 
IKK> homolog, will also induce Ser-536 phosphorylation of p65.  As shown in Fig. 4B, 
WT forms of both IKK> and TBK1 induce p65 Ser-536 phosphorylation however their 
kinase mutant forms (K38A) do not lead to phosphorylation of p65.  Indeed when 
analyzed in detail, kinase mutant forms appear to inhibit the basal level of endogenous 
Ser-536 phosphorylation (compare lane 1 to lane 4 and 6).  It is important to note that the 
phospho-p65 Ser-536 antibody specifically detects only the phosphorylated form of p65, 
and does not cross-react with unphosphorylated p65 (see Fig. 4B).    
 
Analysis of inducible p65 Ser-536 phosphorylation in IKK deficient cells.
Observing that exogenous IKK> induces p65 phosphorylation, we hypothesized that this 
post-translational modification on p65 might be defective in IKK> deficient MEFs in 
response to NF-3B inducers.  To test our hypothesis, IKK> deficient and IKK> and TBK1 
doubly deficient MEFs (DKO) were stimulated with TNFM, a well known NF-3B inducer, 
and compared to similarly treated WT MEFs.  As seen in Fig. 5A, p65 is phosphorylated 
at the Ser-536 position in response to TNF-M as early as 5 min. post-stimulation.  
Interestingly, IKK> deficient cells showed essentially the same pattern of phosphorylation 
kinetics in response to TNFM stimulation.  In addition to p65 phosphorylation, I3BM
degradation was also normal in IKK> deficient cells compared to WT MEF cells.  
Analysis of I-tubulin levels confirmed that loading was essentially equivalent in all lanes 
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(Fig. 5A).  In order to determine if the loss of TBK1 together with IKK> would effect the 
phosphorylation of p65 and I3BM degradation, WT MEFs and MEFs deficient for both 
IKK> and TBK1 (double knock-out MEFs (DKO))  have been used under similar 
experimental conditions. Both p65 phosphorylation and I3BM degradation are normal in 
DKO MEFs (Fig 5B). This result indicated that NF-3B activation as measured by p65 
phosphorylation and I3BM degradation in response to TNF-M is independent of IKK> and 
TBK1.   
 
We next tested the effect of IL-1I on p65 phosphorylation as well as I3B
degradation (Fig. 5C).  IL-1I is, like TNF-M, a well known inducer of NF-3B.  In as early 
as 5 min, p65 is phosphorylated maximally, however, maximal I3BM degradation is 
observed in 10 min. It is interesting again to observe that both p65 phosphorylation at Ser-
536 and I3BM degradation are normal in IKK> deficient cells compared to WT cells.  In 
parallel studies, experiments were also performed in cells where both IKK> and TBK1 
were deleted (DKO) and we observed no significant difference from WT cells relative to 
Ser-536 p65 phosphorylation or IB degradation after stimulation with TNF-M or IL-1I
(Fig 5D). These results suggest a minimal role of IKK> and TBK1 in cytokine induced p65 
phosphorylation and I3BM degradation.  
 
The pathway to NF-JB activation in response to LPS has been characterized in 
molecular detail resulting in the discovery of a novel family of adapter proteins, which 
serve to regulate and polish up TLR responses.  The first identified member of this adapter 
family was MyD88 [74].  The importance of MyD88 in TLR signaling has been confirmed 
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by the inability of MyD88-deficient mice to respond properly to a variety of TLR ligands, 
namely LPS, peptidoglycan and bacterial CpG motifs [19, 34]  Interestingly, analysis of 
MyD88-deficient cells in response to LPS demonstrated the existence of, MyD88-
independent, late NF-JB activation and the induction of IRF-3-dependent genes which has 
recently been verified to be regulated by IKK> and TBK1 kinases [31, 32, 35].  In our 
experimental system, LPS stimulation of WT MEFs and IKK> deficient cells showed 
similar levels of inducible p65 phosphorylation (Fig. 5E).  As expected, the kinetics of the 
phosphorylation upon LPS stimulation is not as fast as TNF-M and IL-1I but the pattern of 
phosphorylation is similar between WT and IKK> deficient cells.  In addition to p65 
phosphorylation, I3BM degradation was also analyzed and there was no defect in this 
process. We next tested the effect of PMA stimulation on p65 phosphorylation and did not 
observe any difference between WT and IKK> deficient MEFs (Fig 5F).  Overall our data 
indicate that inducible Ser-536 phosphorylation is unaffected in IKK> deficient cells, and 
confirm that IKK> is not significantly involved in mechanisms associated with cytokine-, 
LPS-, or PMA-induced I3BM degradation.  
 
IKK controls constitutive p65 Ser-536 phosphorylation. It was surprising to 
observe that IKK> and TBK1 expression led to the phosphorylation of endogenous p65 but 
that MEFs deficient for these kinases depict normal phosphorylation patterns. Since we 
had observed a correlation between IKK and Ser-536 in certain cancer cells, we 
therefore hypothesized that these kinases might be involved in basal or constitutive p65 
phosphorylation.  Since the basal or constitutive level of p65 phosphorylation is quite low 
in MEF cells, the potential that IKK> could contribute to basal/constitutive levels of Ser-
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536 phosphorylation was investigated in HeLa and HEK 293T cells. These cells have 
higher levels of IKK> expression, constitutive p65 phosphorylation and NF-3B activation 
compared to MEFs.  In order to knock-down IKK>, both plasmid based shRNA and 
normal siRNA technologies have been utilized against IKK> mRNA. Additionally, an 
identical control plasmid, which contains a scrambled sequence with no homology to any 
known human gene product, has been utilized.  Extracts from control-treated and siRNA-
treated HeLa cells were analyzed for IKK> knock-down as well as for endogenous p65 
Ser-536 phosphorylation. Our results indicated that transfection of shRNA against IKK>
leads to sustained effective knock down of IKK>. Furthermore, the reduction in IKK>
protein level is well correlated with significant reduction in the basal level of Ser-536 
phosphorylation in HeLa cells as compared to vector control treated cells (Fig. 6A).  
Quantitative Real Time-PCR (qRT-PCR) analysis showed more than a 70% reduction in 
ikk mRNA in HeLa cells when transfected with 2 µg shRNA plasmid (data not shown).  
To show that this is not a cell line specific observation, similar experiments have been 
performed in HEK 293T cells.  In cells where the shRNA plasmid was transfected, IKK>
level were significantly reduced. Again, a significant reduction in Ser-536 phosphorylation 
of p65 was observed, whereas vector control treated cells exhibited no change in IKK>
levels or Ser-536 phosphorylation (Fig. 6B). These results demonstrate that IKK> has a 
significant role in controlling the basal/constitutive p65 phosphorylation at Ser-536 
position in two cell lines.  Interestingly, knock-down of TBK1 with siRNA did not show a 
significant change in p65 phosphorylation at Ser-536 position (Fig. 6C).  This result 
indicates the differential role of IKK> and TBK1 in terms of controlling basal/constitutive 
p65 phosphorylation, at least in the cell types analyzed.   
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IKK knock-down in HeLa cells results in reduced constitutive activity of an NF-*B
dependent promoter. In order to better elucidate the role of IKK> in controlling NF-3B
activity, and to determine if reduction in p65 phosphorylation upon IKK> knockdown is 
correlated with reduced constitutive NF-3B activity, we have analyzed NF-B-dependent 
luciferase reporter assays in HeLa cells. These cells were transfected with either negative 
control siRNA and or with IKK> siRNA for 48 hrs followed by transfection with the 3x-
3B luciferase promoter construct. Importantly knock-down of IKK> in a dose dependent 
manner resulted in reduced promoter activity as compared to the control construct (Fig. 7). 
This result indicates that IKK controls a significant portion of NF-B-dependent activity 
in HeLa cells, presumably through its ability to control Ser-536 p65 phosphorylation.  
 
IKK and p65 phosphorylation positively mediate HeLa cell proliferation. After 
observing that IKK controls basal p65 phosphorylation and NF-3B activity in certain 
cancer cells, we asked if IKK provides cell growth/survival functions. For this purpose, 
MTT cell proliferation assays were performed in HeLa cells transfected with shRNA 
against IKK> or with a non-phosphorylable form of p65 (S536A) expression construct. For 
the data presented in both Figures 8A and B, HeLa cells were seeded in 6 well plates and 
were transfected the next day with the indicated plasmids. 24 hr after transfection, cells 
were reseeded on 96 well plates and the MTT proliferation assay was performed 24 and 48 
hr later. When IKK> is knocked down by shRNA, a significant reduction in cell 
proliferation is observed at the 48 hr time point as compared to control cells transfected 
with the scrambled shRNA plasmid (Fig. 8A). In a similar experimental setting, we tested 
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the effect of IKK mediated p65 phosphorylation on cell proliferation. For the purpose, 
IKK was transfected with WT or a p65 mutant (S536A) that cannot be phosphorylated at 
the Ser-536 position. MTT assays read after 24 hr and 48 hr shows that cells with mutant 
p65 do not proliferate efficiently when compared to cells expressing WT p65. This 
experiment indicates that p65 phosphorylation at Ser-536 is important for HeLa cell 
proliferation.     
 
Discussion
The majority of studies analyzing NF-B activation have focused on induction of 
this transcription factor downstream of cytokine or LPS-dependent signaling. This 
response is generally dependent on the classic IKK complex, containing IKK and IKK.
Additional evidence has indicated that besides the nuclear translocation of NF-3B, post-
translational modifications, like p65 phosphorylation, are required to efficiently activate 
NF-3B dependent gene transcription [41, 75-80].  It is also well established that a number 
of cells, particularly those of cancerous origin, exhibit significantly elevated levels of 
basal or constitutive NF-B activity. In many cases, the origins of this activity remain 
unclear.  
 
Here we show that several cancer cell lines, along with the SV40 large T-
immortalized 293 cell line, exhibit relatively high levels of expression of IKK. This is 
interesting, as IKK is normally considered a kinase that is induced quantitatively by LPS 
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or cytokines. We have investigated a potential role for IKK and TBK1, kinases 
homologous to the catalytically active IKK and IKK subunits, in controlling NF-B
activity, with the focus being phosphorylation of p65 at the Ser-536 position.  Experiments 
were initiated to study IKK> and TBK1 induced NF-3B-dependent promoter activation.   
 
In agreement with previous results [31, 32], IKK> and TBK1, but not their kinase 
mutant forms, strongly activate NF-3B regulated reporter constructs. It is important to note 
that, unlike the 3X-3B promoter, the IFN-I promoter is a complex promoter regulated by 
coordinate actions of NF-3B and other transcription factors, therefore it is not considered 
to be regulated exclusively by NF-3B.  To confirm our reporter assays, gel shift assays 
have been performed.  As expected, IKK> and TBK1 induced significant NF-3B DNA 
binding activity. Super shift assays identified p65 and p50 as main subunits of NF-3B
complex.  Recent studies have shown that post-translational modification of NF-3B
subunits, such as p65 phosphorylation, contribute significantly to NF-3B activation.  
Phosphorylation of p65 at Ser-536 is proposed to be a key modification that potentiates 
p65 transactivation function, and hence NF-3B activation ability [41, 72, 78]. 
 
Recently, it has been reported that overexpression of IKK> or TBK1 together with 
p65, leads to the phosphorylation of ectopically expressed p65 at Ser-536 [40], however, 
this group has not analyzed the endogenous phosphorylation at Ser-536 of p65.  Our 
results clearly support the hypothesis that the kinase activity of IKK> and TBK1 may 
significantly contribute to the constitutive level of S536 phosphorylation of p65.  We have 
also observed that IKK> induces its own expression, which has been shown to be regulated 
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by NF-3B.  This data indicates that ectopically expressed IKK> induces p65 
phosphorylation, NF-3B activation and NF-3B dependent gene expression. It is also raises 
the possibility that IKK functions in an autoregulatory loop, leading to its own 
expression.  
 
It was interesting to observe that IKK> deficient cells show a normal pattern of 
cytokine inducible phosphorylation of p65 and I3BM degradation when compared to WT 
MEFs.  We have tested a series of well known NF-3B inducers (IL-1I, LPS, PMA) that 
are known to activate NF-3B by utilizing different signaling pathways.  Compared to WT 
MEFs, IKK> null cells (and DKO MEFs for both IKK> and TBK1) allowed inducible 
RelA/p65 phosphorylation to the same extent. Why is there no defect in inducible Ser-536 
phosphorylation of p65 in IKK> deficient cells?  The first plausible explanation to this 
question is that the classical IKK signalsome complex is still intact in IKK> deficient cells.  
Therefore, this complex likely compensates for the loss of IKK>. Secondly, there are other 
known and unknown kinases, in addition to IKK complex, that have been claimed to 
mediate Ser-536 phosphorylation of p65 [41, 80, 81] and in the same way, they may still 
induce phosphorylation in IKK> deficient cells.  The third explanation to this question is 
that IKK> and TBK1 are not involved in cytokine induced p65 phosphorylation, but rather 
they are involved in basal/constitutive level of p65 phosphorylation. In one set of 
experiments, this possibility has been investigated.  Since MEF cells have low levels of 
basal p65 phosphorylation and low levels of IKK>, the potential that IKK> and TBK1 
might be involved in constitutive p65 phosphorylation has been investigated in HeLa and 
HEK 293T cells that demonstrate higher levels of IKK> and constitutive p65 
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phosphorylation at Ser-536 position.  IKK> was knocked down by plasmid based shRNA 
technology in both HeLa cells and HEK 293T cells.  Importantly, shRNA transfection 
leads to sustained knock down of IKK> and more importantly, reduction in the IKK> level 
is well correlated with significant reduction in the basal level of Ser-536 phosphorylation 
(Fig. 6), whereas in vector control transfected cells there is no change in IKK> level and 
Ser-536 phosphorylation of p65.  Interestingly knock-down of TBK1 did not reduce the 
basal level of p65 phosphorylation.  Surprisingly this data suggests that TBK1 and IKK>
are not entirely orthologues at least in controlling basal phosphorylation of p65.  As 
suggested earlier [35], IKK> and TBK1 might not be redundant in every signaling pathway 
that they effect. Thus the data presented here clearly show that IKK> does not mediate 
cytokine-induced p65 phosphorylation at the Ser-536 position but has a significant role in 
basal and constitutive phosphorylation of p65 at least in certain cancer cells and in 293T 
cells.  Basal p65 phosphorylation is well correlated with constitutive NF-3B activity, 
which has been implicated in the pathogenesis of many diseases including cancer.  The 
first evidence to our conclusion that IKK> mediates constitutive NF-3B activity came from 
a recent report published while this paper was in preparation [45].  In that study, Eddy et 
al., provided evidences that IKK> contributes to the pathogenesis of breast cancer.  
Expression of a kinase inactive form of IKK blocked breast cancer cell colony formation. 
The results presented in that manuscript are consistent with the findings presented here. 
We have shown that IKK> contributes to the basal/constitutive p65 phosphorylation and 
NF-3B activity as measured by EMSA and NF-3B driven luciferase promoter activity. 
Furthermore, we have also shown that knock-down of IKK> or overexpression of mutated 
version of p65 (S536A) negatively effects the cell proliferation. These findings indicate an 
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important role of IKK> and p65 phosphorylation in cancer cell proliferation.  
 
There have been reports suggesting that IKK> and TBK1 may function as I3B
kinase kinases [29, 82]. Therefore they might function upstream of the classical IKK 
complex (IKKM/I/N).  So we questioned if the phosphorylation of p65 at Ser-536 is a direct 
or indirect effect of IKK>/TBK1.  In other words, IKK> and TBK1 might have activated 
classical IKKs, which then lead to the phosphorylation of p65.  In order to test this, we 
tried to detect activation of IKKI and IKKM by probing the same blots in Fig. 4 with 
commercially available, phospho-IKKM/I antibodies, however we could not detect any 
phosphorylation (data not shown).  Although we cannot rule out that IKK or TBK1 
might function as I3B kinase kinases, our data support a model where these two kinases 
are direct effectors of p65 activation.  There is evidence in the literature supporting this 
model.  First of all, it has been clearly shown that stimulus-coupled I3B degradation and 
p65 nuclear translocation and DNA binding activity of NF-3B is normal in IKK> and 
TBK1 deficient cells despite the fact that there is impaired NF-3B-dependent gene 
transcription [35, 36, 39]  This evidence supports the fact that the activity of IKKM and 
IKKI is normal in IKK> or TBK1 deficient cells, since there is normal I3B degradation, 
normal p65 nuclear translocation and normal DNA binding activity.  We believe that our 
data, together with these findings, emphasize the RelA/p65 as the physiological target of 
IKK> and TBK1 under basal growth situations, at least in certain cells.  If IKK> and TBK1 
were upstream of classical IKKs, one would expect a deficiency in one of the above 
processes which are tightly regulated by IKKM and I.
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Very recently an article has been published indicating that IKK> mediates 
inducible phosphorylation of NF-3B p65 at serine 468 but not at serine 536 during T cell 
costimulation [83]. However, the outcome of the phosphorylation at Ser-468 by IKK> has 
not been shown, and the phosphorylation at this site by GSK-3I has been claimed by the 
same group to be associated with negative NF-3B regulation [40].  
 
To summarize, we have provided evidence that IKK, and not TBK1, controls the 
constitutive NF-B activity in certain cancer cells and in 293T cells. This evidence is 
supported by siRNA experiments and by associated reporter studies. It is presently unclear 
whether IKK functions separately from the classic IKK complex, or through distinct 
regulatory pathways. It is also unclear whether IKK is the kinase that directly controls 
Ser-536 p65 phosphorylation.  Nevertheless, the data indicate a potentially important role 
for IKK in controlling at least part of the constitutive NF-B activity generated in certain 
cancer cells, with subsequent downstream effects on cancer cell proliferation.  
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Figures and Legends
Figure 1.1:  IKK expression is elevated in a number of cancer cells. Total cell extracts 
from indicated cell lines have been prepared and immuno-blotted with indicated 
antibodies. IKK> expression is elevated in many cancers cells and the level of the 
expression is well correlated with p65 phosphorylation at Ser-536. The levels of IKKM,
IKKI and TBK1 are not consistently correlated with p65 phosphorylation level. 
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Figure 1.2:  IKK and TBK1 but not their kinase mutant forms activate NF-*B dependent 
reporter and IFN4 promoter. HEK 293T cells seeded in 24-well plate were transiently co-
transfected the next day with an expression vector for IKK>, TBK1 or their kinase mutant 
forms  and vector encoding a reporter gene for 3x-3B reporter (A) and IFNI promoter (B).  
Experiments are done at least twice in triplicate and luciferase reporter gene activity was 
measured 24-48 hr after transfection.  (C) IKK> activates NF-3B dependent promoter in a 
concentration dependent manner.  Indicated concentration of IKK> and its kinase mutant 
form were co-tansfected with 3x-3B reporter gene constructs in 48-well plate.  
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Figure 1.2 
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Figure 1.3:  IKK induces significant NF-*B DNA binding activity. (A) HEK 293T cells 
seeded in 10 cm dishes were transfected with expression vector for IKK> or empty vectors 
for 48 hr.  Indicated cells were treated with 10 ng/ml TNF-M for 30 min.  Protein-DNA 
complex is resolved by EMSA technique as described in materials and methods.  TNF-M is 
included in the experiment for the control purposes.  The NF-3B complex and the free 
probe are indicated by the arrows. Western blot analysis of cytoplasmic extracts is shown 
in the lower panel for the analysis of IKK> expression (B) NF-3B complex induced by 
IKK> and TNFM is mainly composed of p65 and p50 heterodimers.  Each lane in Fig 3A 
has been shifted with indicated antibodies. The numbers on the top (1-4) show the lane 
numbers in Fig. 3A. RelA/p65 or p50 binding activity was assessed by incubation of 5 µg 
nuclear extracts with either p65 or p50 specific Abs followed by EMSA. In the lanes 
where an NF-3B complex is detected (2, 3, 4), there is a supershifted band with the p65 
and p50 antibodies. ”ns” stands for non-specific binding. 
.
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Figure 1.4:  IKK and TBK1 expression leads to phosphorylation of endogenous p65 at Ser-
536. (A) IKK> expression induces p65 phosphorylation and its own expression.  HEK 293T 
cells were transiently transfected with 1Xg of the GFP-IKK> expression vector.  Whole cell 
lysates were prepared 24 hr after transfection and blotted with p65 phospho specific antibody 
that detects phosphorylation at Ser-536 position (indicated as P-p65 (Ser-536)).  Notably, 
endogenous IKK> expression is induced by ectopically expressed  
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Figure 1.5: p65 phosphorylation at Ser-536 position is normal in IKK deficient MEFs in 
response to different stimuli. Cytokine induced p65 phosphorylation in IKK> singly deficient 
and IKK> and TBK1 doubly deficient MEFs is comparable to WT MEFs.  Indicated MEF 
cells were seeded in 6-well plates and at 70-80 % confluency they were stimulated with 10 
ng/ml TNFM (A, B), 10 ng/ml IL-1I (C, D) 1 µg/ml LPS (E) and 100 ng /ml PMA (F) for 
indicated time points. Whole cell extracts were prepared and blotted with indicated 
antibodies.  Interestingly in all of the stimuli tested, there was no significant difference in 
terms of either p65 phosphorylation pattern or I3BM degradation kinetic in IKK> deficient or 
DKO MEFs compared to WT MEF cells.  Analysis of I-tubulin levels confirmed that loading 
was essentially equivalent in all lanes. 
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Figure 1.6:  Sustained knockdown of IKK leads to impaired Ser-536 phosphorylation of 
p56. (A, B) Vector encoding shRNA targeting IKK> or vector control (VC) alone was 
transfected in HeLa cells (A) in 6-well plate with increasing concentration of IKK> shRNA 
vector (1, 2, 3 µg/well shRNA plasmid) or in HEK 293T cells (B) for 72 hrs.  Lysate 
preparation and western blots are done as described above.  A significant knock-down in 
IKK> level was well correlated with reduction in p65 Ser-536 phosphorylation whereas there 
is no change in total p65 level.  I-tubulin level is shown to demonstrate equal loading in all 
lanes.  (C) siRNA targeting TBK1 was transfected in HeLa cells for 72 hr.  As shown, 
despite the significant reduction in TBK1 level, no significant change in p65 phosphorylation 
was observed. 
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Figure 1.7:  IKK knock-down in HeLa cells leads reduction in basal activity of NF-*B
dependent promoter. HeLa cells seeded in 6 well plates were transfected by siRNA targeting 
IKK> or negative control (NC) siRNA at indicated concentration for 48 hr.  Then cells were 
split to 24 well plates and were transfected with 3X-3B promoter and Renilla Luciferase 
promoter as an internal control.  siRNA was also included in this transfection complex to 
give a second hit for IKK> knock-down.  At indicated concentrations of siRNA (20 and 40 
nM), knock-down efficiency of IKK> mRNA was 58% and 79% respectively as measured by 
QRT-PCR (Data not shown).  Reduction in IKK> level is well correlated with the reduction 
in basal activity of an NF-3B dependent promoter. 
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Figure 8: IKK and p65 phosphorylation mediates cell proliferation. Hela cells seeded in 6 
well plates were transfected with indicated plasmids for 24 hr, then cells were trypsinized 
seeded in 96 well plate in triplicates. After indicated time points, MTT assay has been 
performed. Results are representative of two independent experiments done in triplicates. 
When IKK> level has been modified by shRNA, cell proliferation was not as efficient as 
control shRNA transfected cells. IKK> knock-down with shRNA after 48 hr reduced cell 
proliferation significantly (A). Si-VC and Si-IKK> stands for vector control shRNA and 
shRNA against IKK> respectively. IKKe was  also overexpressed together with WT and  
S536A mutant version of p65 to test the significance IKK> mediated of p65 phosphorylation 
(B). Although IKK> and WT p65 transfected cells proliferate slightly better than vector 
control transfected cells,  when IKK> was overexpressed with S536A mutant version of p65, 
which can not be phosphorylated at ser 536 position was, there was significantly less cell 
proliferation. These data suggest that both IKK> level and p65 phosphorylation status is 
important for proper cell proliferation. 
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Materials and methods
Reagents and materials: All cells were cultured in Dulbecco’s modified Eagle’s medium 
(DMEM), complemented with 10% fetal calf serum (FCS), 100 units/ml penicillin, 100 
Xg/ml streptomycin.  Generation of Wild type, IKK> single  and IKK>- TBK1 double 
knockout cells were described previously [35] and were the kind gift of S. Akira. A  
monoclonal antibody against Flag (M2) was obtained from Sigma.  An antibody to IKK> and 
to phospho-specific NF-3B p65 (Ser-536) were obtained from Cell Signaling.  Antibodies to 
I-tubulin and to I3BM were obtained from Santa Cruz.  Antibodies to IKKM and IKKI were 
obtained from Upstate Biotechnology Inc.  LPS (L6529, Sigma) was used at a final 
concentration of 1 µg/ml. rhTNF-M (Promega) was used at a final concentration of 10 ng/ml.  
Recombinant mouse Interleukin- 1I (mIL-1I)(Roche Applied Sciences) was used at a final 
concentration of 10 ng/ml.  Effectene transfection reagent obtained from Qiagen was used 
according to the manufacturer’s protocol.  
 
Plasmids and Constructs: 3X-3B luciferase reporter construct contains 3 3B consensus DNA 
binding sites from the MHC class I promoter fused upstream of firefly luciferase. Wild type 
and kinase mutant forms of Flag-tagged IKK> (IKK> K38) have been described previously 
[27]. Wild type and kinase mutant forms of TBK1 (TBK1 K38) have been described 
previously [32] were the kind gift of J. Hiscott. pLuc-110 IFNI reporter constructs have been 
described previously [31] and were the kind gifts of T. Maniatis. 
 
Transfections and Reporter assays:  For transient transfections, the indicated cell lines were 
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seeded in 6-well plates at 30-50 % density and transfected the next day with the indicated 
expression vectors for 48 hrs using Effectene (Qiagen) transfection reagent according to the 
manufacturer’s instruction.  For reporter assays, 2 x 105 cells were seeded in 24 well plates 
and were co-transfected the next day with the indicated luciferase reporter genes and a I-
galactosidase reporter gene as an internal control.  The total amount of transfected DNA (500 
ng DNA) in each well was adjusted by adding empty plasmid vector (pcDNA3.1).  
Luciferase activity of whole cell lysates was measured by using a luciferase assay kit 
(Promega).  I-galactosidase activity was measured by Liquid I-Gal assay with CPRG 
substrate.  Relative luciferase activity was calculated by normalizing to I-gal expression 
values.  Luciferase fold induction was calculated by normalizing to control treatment which 
was assumed as 1 fold induction. 
Western Blot: After stimulation, cultured cells were lysed on ice for 5 min in RIPA lyses 
buffer with freshly added protease and phosphatase inhibitor cocktails.  Lysates were cleared 
by centrifugation at 4 °C for 15 min at 13,000 g. The amount of total protein was measured 
and equal amounts (20 µg) were fractionated by NuPAGE Novex 4-12% Bis Tris gels 
(Invitrogen) and electro-transferred to polyvinylidene difluoride membranes.  Membranes 
were blotted with the indicated antibodies, and proteins were detected using an enhanced 
chemiluminescence detection system (Amersham Biosciences, Freiburg, Germany).  Where 
indicated, membranes were stripped and re-probed with the indicated antibodies. 
 
Electrophoretic Mobility Shift Assay (EMSA): EMSAs were performed as previously 
described [23].  Briefly, 4[5 µg of nuclear extracts prepared following cell stimulation were 
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incubated with a radiolabeled DNA probe containing an NF- B consensus site.  For 
supershifts, 1 µl of anti-p65 antibody (Rockland) or 2 µl of anti-p50 antibody (Santa Cruz, 
SC-7178) was added and the binding reaction was allowed to proceed for an additional 15 
min.  Protein[DNA complexes were resolved on a non-denaturing polyacrylamide gel and 
visualized by autoradiography. 
 
siRNA & shRNA transfection: IKK> mRNA was knocked down with the GeneSupressor 
System (IMGENEX).  Plasmids encoding control shRNA and IKK> shRNA were transfected 
by Effectene transfection reagent (Qiagen) according to manufacturer’s instructions for 48-72 
hr. Additionally, Silencer® predesigned siRNA targeting IKK> and TBK1 have also been 
utilized and were transfected with Silencer™ siRNA Transfection II Kit. Lysate preparation 
and westerns were performed as described.
Cell proliferation, MTT assay: Cell proliferation assay has been performed as described by 
TACS MTT assay kit (R&D systems).  First, the optimal cell number, which was 1x104 for 
Hela cells in our system, has been determined. After transfection, equal number of cells has 
been seeded in 96 well plate for indicated times. 10 µl of MTT reagent was added to each 
well including the blank wells, and incubated for 4-5 hrs at 37 0C. Then 100 µl of detergent 
reagent was added, incubated for at least 12 hr at 37 0C and absorbances at 570 nm were 
measured with reference wavelength of 650 nm. 
 
CHAPTER II 
 
Regulation of Bcl-3 proto-oncogene expression by IKK < (epsilon) 
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Abstract
We have previously demonstrated that IKK-i / IKK (epsilon) is expressed in a 
number of cancer cells and is involved in regulation of constitutive NF-B activity that 
mediates cell proliferation [44]. Here we present evidence that Bcl-3 is an important 
downstream IKK regulated gene that is potentially the mechanistic link between IKK and 
cell proliferation. Research from our lab has recently indicated Bcl-3 as an important 
suppressor of persistent p53 activity [84]. Bcl-3 was identified by microarray analysis of 
gene expression profiles in Hela cells with RNAi mediated IKK knock-down. Here we 
demonstrate that IKK knock-down leads to significant reduction in Bcl-3 mRNA and 
protein level, and exogenous expression of IKK significantly upregulates Bcl-3 gene 
expression. Furthermore, basal as well as inducible Bcl-3 gene expression is diminished in 
IKK knock-out MEF cells. Data presented here suggests that Bcl-3 gene expression is NF-
B p65 dependent but IKK/ independent. Interestingly, IKK is able to phosphorylate p65 
in IKK/ DKO cells, which we think explains how p65 regulates Bcl-3 gene expression 
independent of IKK/. Significant correlation between IKK> and Bcl-3 expression has been 
observed in HCC tumors compared to adjacent tissue. Moreover, MCF-7 cells stably 
expressing Bcl-3 proliferate more efficiently than the parental cells suggesting that Bcl-3 is 
an important mediator of cell proliferation and is potentially the mechanistic link in IKK
induced cell survival and proliferation. 
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Introduction
Bcl-3 was identified 20 years ago by molecular cloning of  the breakpoint of the 
t(14;19) chromosomal translocation from a subset of human B-cell chronic lymphocytic 
leukemias [48]. Translocation at this point leads to Bcl-3 overexpression that results in 
dysregulation of mostly unexplored downstream target genes that are predicted to be 
involved in differentiation, cell survival and apoptosis [49].  
 
Bcl-3 is a member of the ankyrin-repeat-containing IB family of NF-B inhibitors 
[3]. Although it shares significant structural features with IB proteins [50, 51], Bcl-3 
contains two transactivating domains and can function as a transcriptional activator or 
repressor by forming heterocomplexes with the NF-B p50 or p52 subunits in a 
phosphorylation dependent manner [51-55]. Although the molecular mechanism of Bcl-3 
dual function is poorly understood, some observations explain how Bcl-3 may act as both 
transcriptional activator as well as repressor. It was suggested that Bcl-3 can potentially act 
as a transcriptional activator by removing repressor p50 homodimers from the B sites [51] 
and also by acting as a bridging factor between NFB and other coactivators such as JAB1, 
Bard1 and Tip60 [56]. Similarly, upon IL-1 stimulation, Bcl-3 recruits Tip60 
acetyltransferase containing activator complex to the promoter region of specific subset of 
NF-B dependent genes [57]. Moreover, Bcl-3 was also suggested to function as a 
coactivator itself by regulating the expression of subset of NF-B dependent genes in 
response to TNF [58]. In contrast to its transactivator potential Bcl-3 has also been 
suggested to act as a transcriptional repressor. It has been demonstrated that Bcl-3 can 
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physically interact with HDAC-1, -2 and -3 which are involved gene repression [59]. 
Another study also demonstrated that Bcl-3 inhibits LPS induced inflammatory responses in 
macrophages by recruiting HDAC-1 [60]. Although the opposite dual function of Bcl-3 is 
poorly understood, one explanation may come from the posttranslational modifications on 
Bcl-3 or Bcl-3 interacting proteins. Bcl-3 has two residues within its C terminal domain that 
are phosphorylated by GSK3 kinase which mediates its interaction with HDAC1 and induce 
its degradation through proteosome pathway [59]. Although protein phosphorylation was 
suggested to be the key mechanism for regulation of Bcl-3 activity [61], other 
posttranslational modifications such as ubiquitination was recently demonstrated to be 
critical for Bcl-3 nuclear translocation [62]. For instance, It was clearly demonstrated that 
TPA or UV light triggers the translocation of CYLD from the cytoplasm to the perinuclear 
region, where CYLD binds and deubiquitinates Bcl-3, thereby preventing nuclear 
accumulation of Bcl-3 and p50/Bcl-3- or p52/Bcl-3-dependent gene expression and 
subsequent cell proliferation [62].  
 
Bcl-3 has been implicated in many crucial physiological events such as cell 
proliferation, immune, inflammation and cancer progression. The results from Bcl-3 knock-
out mice revealed critical roles for Bcl-3 in antigen-specific priming of T and B cells. Bcl-3 
deficient mice are also impaired in germinal center reactions and T cell-dependent antibody 
responses to influenza virus and have partial loss of may underlie the immunologic defects 
[63, 64]. It was shown that  Bcl-3 associates with NF-B p50 or p52 subunits and strongly 
enhances cell proliferation and oncogenesis  through activation of the cyclin D1 promoter 
[23, 65]. In line with these observations, EµBcl-3 transgenic mice develop 
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lymphoproliferative disorders such as; Lymphadenopathy, splenomegaly, and altered 
immunoglobulin production [66]. Furthermore,  although the mechanism is poorly 
understood, Bcl-3 was shown to directly transform cells [59].  Research demonstrated that 
Bcl-3 exerts antiapoptotic activity in B and T lymphocytes [67, 68] and controls the death of 
activated T cells [69]. Despite its well established role in cell proliferation and apoptosis, the 
signaling pathways and upstream key effecters that activate Bcl-3 gene expression are poorly 
understood. 
 
IKK was initially identified as PMA inducible kinase [27], which is identical to a 
kinase named IKK-i identified via its induction downstream of LPS-induced signaling [19].  
IKK> in turn is closely related to another IKK-related kinase designated as TBK1 [28] or 
NAK [29].  TBK1, which is highly homologous to IKK>, binds to TANK and TRAF and 
may form an alternative IKK complex consisting of IKK> and TBK1 [28]. IKK> and TBK1 
have been shown to play important roles in the innate immune response by functioning as 
critical kinase components of the interferon regulatory factor 3 (IRF3) and IRF7 signaling 
pathways involved in responses to viral infection or dsRNA treatment [31, 32]. In addition to 
their well established roles in IRF3 and IRF7 activation during innate immunity, recent 
studies implicated the involvement of IKKe in cancer mechanism by several groups 
including us [44-46]. Interestingly TBK1 has also been implicated in tumor cell survival 
[47].
Although research from several groups recently appreciated the implication of IKK
and TBK1 cancer progression and tumor cell survival, the molecular mechanism of IKK and 
TBK1 induced cancer signaling and their downstream target genes remain to be identified. 
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Here we report Bcl-3 as one of the important target genes downstream of IKK that is 
important in cell proliferation and cell survival. Microarray analysis and subsequent 
biochemical experiments indicated that Bcl-3 is transcriptionally regulated by IKK in a NF-
B p65 dependent manner. Moreover, Bcl-3 expressing MCF-7B cells proliferate more 
efficiently than the parental MCF-7 cells. Our data suggest that Bcl-3 is an important 
mediator of cell proliferation downstream of IKK and is potentially the mechanistic link in 
IKK-induced cell survival and proliferation. 
 
Results
Identification of Bcl-3 as IKK target gene: We have previously demonstrated that IKK is 
an important mediator of NF-B activity in cancer cell-associated signaling mechanism [44]. 
Our subsequent research has focused on understanding and identifying IKK-regulated genes 
and downstream signaling mechanisms at the genome wide level. HeLa cells have been used 
since they display significant basal IKK expression as in many other cancer cell lines. 
IKK mRNA levels were knocked down by siRNA technology. RNA from samples where 
there is at least 75-80 % IKK knock down was subsequently processed and hybridized to 
Affymetrix Human Genome Plus U133 Plus 2.0 as described in the materials and methods 
section. Among a number of potentially interesting genes (Fig. 2.1B) whose expression has 
changed 2 fold or more at the basal level upon IKK knock-down, Bcl-3 was especially 
interesting for us because of our previous research demonstrating the importance of Bcl-3 in 
cell survival and proliferation. Several publications from our lab have demonstrated that Bcl-
3 is over expressed in human tumors, drives cyclin D1 gene expression and negatively 
regulates p53 signaling [23, 84, 85]. It was interesting to see from the literature and our own 
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studies that both Bcl-3 and IKK are overexpressed in number of cancer cell lines and human 
tumors and that there is a strong positive correlation between IKK and Bcl-3 mRNA levels 
from microarray experiments. These observations led us to analyze if IKK is the key 
regulator of Bcl-3 gene expression. 
 
IKK knock-down by Si-RNA reduces, and expression of IKK induces Bcl3 gene expression:
In order to validate the microarray results IKK was knocked-down in an independent 
experiment.  IKK targeted siRNA treatment significantly reduced Bcl-3 both at the mRNA 
level as well as at protein level in HeLa cells. Total RNA from negative control and IKK
targeted Si-RNA treated samples were prepared and Bcl-3 and IKK mRNA levels were 
quantified with qRT-PCR (Figure 2.2A). In addition to mRNA levels, IKK knock-down 
significantly reduced Bcl-3 protein levels in HeLa cells.  Total cell lysates from different 
IKK si-RNA and the negative control (NC) si-RNA treated samples were prepared after 72 
hrs of si-RNA treatments. Different si-RNA against IKK have been used and we could only 
knock-down IKK effectively with product si-RNA ID number 919 from Ambion (Figure 
2.2B). In addition to gene knock-down experiments, we wanted to test if exogenously 
expressed IKK can induce Bcl-3 gene expression. Transiently expressed WT IKK, but not
its kinase mutant form (IKK KM), induced significant endogenous Bcl-3 gene expression 
(Fig. 2C). Importantly, kinase mutant IKK (IKK KM) reduces the basal level of Bcl-3 gene 
expression which suggests that kinase activity of IKK is important for its function in terms 
of regulating Bcl-3 gene expression. Moreover, expression of non-degradable form of IB
(IB super repressor (SR)) inhibits IKK induced Bcl-3 gene expression however p65 
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expression significantly up regulates it. In line with overexpression studies, promoter 
analysis of Bcl-3 also indicated that IKK is an important regulator of Bcl-3 gene expression 
(Fig. 2.2D). WT IKK but not its kinase mutant form induces significant luciferase activity 
from a construct that has Bcl-3 promoter and an intronic enhancer that has been previously 
shown to be NF-B responsive [86]. These results suggest that IKK control Bcl-3 gene 
expression in a NF-B dependent manner.  In line with previous observations that  Cyclin D1 
is one of the Bcl-3 target gene [23, 65] we note that exogenous WT IKK expression is able 
to induce cyclin D1 gene expression over 50 %. This increase in cyclin D1 gene expression 
over the basal level may not seem too much of a fold induction; however, if this effect is true, 
in a tumor setting, a 50 % increase would give greater advantage to those cells that have 
higher Cyclin D1 expression. 
 
Basal levels as well cytokine induced levels of Bcl-3 gene expression are defective in  IKK
KO MEF cells: Next, IKK mediated regulation of Bcl-3 gene expression was explored in 
MEF cells that are deficient for IKK. For this reason, WT MEF as well as IKK deficient 
MEF cell lines have been utilized. First, Bcl-3 gene expression at the basal level was 
analyzed in both WT as well as IKK deficient MEF cell line. As shown in Figure 2.3A, 
IKK deficient cells have significantly low levels of Bcl-3 mRNA. This further enhances the 
idea that IKK is an important mediator of Bcl-3 gene expression.  In order to explore 
inducible regulation of Bcl-3 gene expression, WT MEFs as well as IKK deficient MEFs 
were treated with LPS for indicated times, and Bcl-3 mRNA levels are quantified with qRT-
PCR. As shown, in Figure 2.3B, cells deficient for IKK have significantly lower levels of 
total Bcl-3 message level. Although there is some induction of Bcl-3 in IKK deficient cells, 
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compared to WT cells the total induction is significantly less. In addition to the mRNA level, 
Bcl-3 protein expression is also defective in IKK deficient cells. As shown in Fig. 2.3C, 
there is a detectable Bcl-3 gene expression 6 hours after LPS induction, however, this cannot 
be detected in IKK deficient cells. It is interesting to observe that Bcl-3 is well induced in 
WT MEFS, however IKK deficient cells does not show any detectable Bcl-3 protein 
expression in response to LPS. Data presented here strongly suggest the transcriptional 
regulation of Bcl-3 gene expression by IKK.
IKK and IKK independent. but NF-kB p65 dependent Bcl-3 gene expression: Bcl-3 gene 
expression has been reported to be regulated by different transcription factors [68, 86]. Since 
we previously reported that IKK mediates constitutive NF-B in cancer, we wondered if the 
role of NF-B signaling pathway in regulating Bcl-3 gene expression. For this purpose, MEF 
cells that are p65 knock-out (KO), and IKK and IKK double knock-out (DKO) have been 
utilized. Interestingly in p65 deficient MEFs there is significantly less Bcl-3 gene expression 
at the basal level and there is little or no induction of Bcl-3 in p65 deficient cells upon  TNF
treatment for over 7 hr period (Fig. 2.4A). This result clearly indicates that NF-B p65 is an 
important mediator of Bcl-3 gene expression as has been suggested before [86]. Since most 
of the canonical NF-B signaling comes from IKK and IKK, we wanted to test the role of 
the classical IKK complex in Bcl-3 gene expression. As shown in Figure 2.4B, there is no 
significant difference in the level of Bcl-3 gene expression in IKK/ DKO MEFs and WT 
MEFs. Both basal and inducible levels seem to be comparable, if not more, in DKO cells. 
These results suggest that Bcl-3 gene expression is controlled by NF-B p65 by non-classical 
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NF-B kinases. Importantly, as an example of one of these kinases, we and other groups 
have shown that p65 is phosphorylated by IKK [40, 44, 83].  
 
IKK - and IKK -independent phosphorylation of p65 by IKK: The data showing that Bcl-
3 gene expression is independent of IKK/ but p65 dependent was in line with the 
observation that there are other IKK related p65 kinases like IKK and TBK1 besides IKK
and IKK. Although there is no doubt that IKK and TBK1 are involved in p65 
phosphorylation, there is no direct evidence proving that they are direct kinases and therefore 
they are suggested to act as IB kinase (IKK) kinases rather that direct mediators of p65 
activation [26]. These observations lead us to investigate if IKK can function independent of  
IKK and . To test our hypothesis, we have over expressed IKK in IKK and IKK
double knock-out MEFs, and try to see if p65 can still be phosphorylated in the absence of 
IKK/. Interestingly, there is significant p65 phosphorylation in the lane 6, where IKK and 
p65 is exogenously expressed in IKK/ DKO cells (Fig. 2.5). It is important to note that 
TNF-induced p65 phosphorylation is significantly reduced in IKK/ DKO cells compared 
to WT cells (Fig 5, compare lane 2 and lane 4). Inline with previous observations, the data 
presented here suggest that IKK and IKK are the main p65 kinases upon cytokine 
induction, however the fact that IKK can phosphorylate p65 in the absence of IKK and 
IKK suggests that IKK functions independent of IKK/ at least in terms of p65 
phosphorylation. It is important to note that p65 can be co-immunoprecipitated with flagged 
tagged IKK, which suggest that they interact with each other, and the phosphorylation of 
p65 by IKK is a direct effect (data not shown). 
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Bcl-3 over expressing cells proliferate more efficiently: We previously reported that one of 
the physiological roles of IKK is to provide proliferative signaling in cancer cells and that 
IKK overexpressing cells proliferate more efficiently [44, 45]. In order understand if Bcl-3 
is the main mediator of IKK induced cell proliferation, we speculate that Bcl-3 
overexpressing cells should proliferate more efficiently than the parental cells. In order to test 
this hypothesis MCF-7B cells where there is stably expressed Bcl-3 gene [84] have been 
utilized together with parental MCF-7 cells. As shown in Figure 2.6, MCF-7B cells, where 
there is stable Bcl-3 expression, proliferate more effectively than the control cells as 
measured my MTT cell proliferation assay over a period of 4 days. The same numbers of 
cells were seeded in 94 well plate and at indicated time points MTT assay has been 
performed. Results presented here are perfectly in line with the fact that Bcl-3 is an important 
mediator of CD1 gene expression, hence  provide proliferative and prosurvival signals to 
cells [23, 67, 68]. These results suggest that Bcl-3 is potentially a mechanistic link between 
IKK and cell proliferation probably through activating CD1 gene expression. Experiments 
are now testing the effects of Bcl-3 knock-down on cell growth control. 
 
Bcl3 and IKK overexpression in human HCC tumor samples: Significant Bcl-3 
overexpression has been observed in human hepatocellular carcinoma (HCC) tumors 
compared to adjacent tissue sections (Bert O’Neil, Personal communication). In order to 
understand if there is any correlation between Bcl-3 overexpression with IKK level in these 
tumor samples, we have analyzed Bcl-3 mRNA levels as well as IKK mRNA levels and 
protein level in different human tumor samples by qRT-PCR and western blot respectively 
both in adjacent tissue (A) and in tumor sectionsz (T). As shown in Fig 2.7A, there is 
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significant Bcl-3 overexpression in sample # 2, 3 and 4 specifically in tumor section 
compared to adjacent tissue. (A= adjacent tissue, T= tumor). In line with this, there is also 
significant IKK overexpression in these samples as well as in sample # 1 (Fig 2.7B). We 
have observed significantly higher IKK protein expression specifically in tumor section of  
almost all of the tumor samples (Fig 2.7C). Although there is higher IKK protein level in 
sample #5, neither Bcl-3 nor IKK message level is higher in sample #5 compared to 
adjacent tissue section. Although we do not know exactly why, we speculate that there might 
have been miss labeling or RNA degradation during handling process. Over all, there is high 
correlation between IKK overexpression and Bcl-3 overexpression in tumor section 
compared to adjacent tissue; suggesting that, in line with our genetic and biochemical 
evidences, strong Bcl-3 overexpression in these tumor sections is likely driven by IKK.
Discussion
IKK and a related kinase TBK1, are classical I-B kinase (IKK) related kinases 
whose importance in cell proliferation, survival and hence cancer mechanism are recently 
being appreciated. We have previously shown that IKK is involved in constitutive, cancer 
cell associated NF-B activity that provides signaling mechanism for efficient proliferation 
and survival [44]. In addition, several other groups have also implicated IKK in cell 
proliferation, survival and apoptosis [45, 46]. Importantly, IKK related kinase, TBK1 
pathway activation has recently been shown to inhibit apoptosis in tumor cells [47] Currently 
there is an unmet requirement of dissecting the signaling pathways downstream of IKK and 
TBK1 and identifying their target genes that are critical for cell survival, proliferation and 
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hence tumor formation. Here we describe Bcl-3 as one of those target genes downstream of 
IKK.
There is ample evidence in the literature implicating Bcl-3 in cell cycle, immunity
and inflammation; however, currently there is an unmet requirement of identifying the
upstream signaling mechanism and effectors of regulation Bcl-3 gene expression. Here, we
report that that IKK is important regulator of Bcl-3 gene expression. Identification through 
microarray analysis of genes that are affected by IKK knock-down, and subsequent 
validation biochemical experiments suggested that Bcl-3 gene expression is regulated by 
IKK in a NF-B dependent manner. In addition, our data suggest that regulation of Bcl-3 by
IKK is potentially the mechanistic link and the main mediator of IKK induced cell
survival/proliferation.
Currently we have modest information about the regulation of Bcl-3 gene expression, 
apart from the fact that chromosomal translocation at t(14;19)(q32.3;q13.2) in B-CLLs leads
to Bcl-3 overexpression. We and others have demonstrated that Bcl-3 can be inducibly
expressed by DNA damaging agents or some cytokines [16, 22, 84, 87]. Moreover, Bcl-3
expression can be induced by estrogen withdrawal and mediate growth and hormonal
independence in breast cancer cells [88]. We have observed selective Bcl-3 overexpression in
human breast tumors [85] and reported that Bcl-3 can induce CD1 gene expression [23].
Here we show that IKK significantly upregulates Bcl-3 gene expression. Importantly, cyclin
D1 gene expression was also observed which is a probably consequence of Bcl-3 gene
expression.
Upstream effectors and transcription factors regulating Bcl-3 gene expression have
not been fully investigated. One study reported that Bcl-3 expression is upregulated
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following IL-4 deprivation under the control of AP1 and AP1-like transcription factors [68].
However, Bcl-3 expression was also shown to be regulated by NF-B transcription factor
through an intronic enhancer in T lymphocytes [86]. Whether Bcl-3 is an NF-B or AP1
dependent genes, or if each transcription factors regulates differentially under different
circumstances remains to be identified. Our data presented here suggest that NF-B p65 is an
important mediator of Bcl-3 gene expression. In p65 KO MEFs, there is significant reduction
in the basal level of Bcl-3 mRNA and it cannot be induced upon cytokine stimulation.
Interestingly, IKK/ which are the main NF-B kinases did not seem to be involved in Bcl-
3 gene expression. This data suggested the activation of p65 by a third kinase other than
IKK/. Recently, several groups including us reported that IKK is an important p65 kinase
that phosphorylate at Ser 536 position and contribute to NF-B regulated gene expression
and cell proliferation [40, 44, 45]. Previously, IKK and TBK1 were suggested to act as
upstream kinases of IKK complex [26]. Whether IKK induces p65 phosphorylation directly
or act as an upstream kinase of IKK is currently unknown. We present evidence here that this
phosphorylation is a direct effect. First of all, IKK can induce p65 phosphorylation in
IKK/ double knock-out MEF cells (Fig. 2.5). Furthermore, p65 can be co-
immunoprecipitated with IKK (Data not shown). In addition to this, from the previous 
research in the literature, we know that stimulus-coupled I3B degradation and p65 nuclear 
translocation and DNA binding activity of NF-3B is normal in IKK> and TBK1 deficient 
cells despite the fact that there is impaired NF-3B-dependent gene transcription [35, 36, 39, 
44]. This evidence supports the fact that the activity of IKKM and IKKI is normal in IKK> or
TBK1 deficient cells, since there is normal I3B degradation, normal p65 nuclear 
translocation and normal DNA binding activity. Although we cannot rule out the possibility 
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IKK might function as I-3B kinase kinase, our data support a model where IKK is a direct 
mediator of p65 activation and is working in parallel with classical IKK complex 
differentially under different circumstances.  
 
Bcl-3 has been implicated in many crucial physiological events such as cell 
proliferation, immune, inflammation and cancer progression. We have also observed that 
cells with a stable Bcl-3 expression priloferate more efficiently than parental cell lines.  Bcl-3 
induced Cyclin D1 upregulation and inhibition of apoptosis are probably the two main 
mechanism that accounts for better survival and proliferation in Bcl-3 expressing cells. Bcl-3 
upregulation has been observed in many cancer types [85, 89, 90] and hepatocellular 
carcinomas and pancreatic cancers (Bert O’Neil, unpubl.).  Interestingly most of these 
cancers have elevated basal NF-B activity and we have reported that IKK is the major 
player of cancer cell associated NF-B activity. We have observed strong correlation 
between IKK expression and bcl-3 gene expression specifically in the tumor section of 
hepatocellular carcinomas samples compared to the adjacent tissue section (Fig. 7), which 
suggests that IKK is driving Bcl-3 gene expression in tumor settings.  Previous research and 
the data presented here so far indicate that IKK is an important mediator of constitutive NF-
B activity in cancer cells and Bcl-3 is one of the important target gene that is upregulated 
downstream of IKK induced NF-B activity.  
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Figures and Legends
Figure 2.1: Identification of Bcl-3 as IKK target gene: IKK mRNA level was knockdown 
by siRNA technology in HeLa cell lines and the RNA from samples where there is at least 
75-80 % IKK knock down we subsequently processed and hybridized to Affymetrix 
Human Genome Plus U133 Plus 2.0 as described in materials and methods section.  Genes 
whose expression has changed 2 fold or more at the basal level upon IKK knock-down were 
analyzed from two independent experiments. List of genes whose expression has changed 
more than two fold upon IKKe knock-down by siRNA treatment as identified by microarray 
technology (Fig. 2.1 B). 
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Figure 1 
A
Si-RNA treatment for 48 hr
(IKK vs Negative control)
RNA isolation,
cRNA synthesis
Hybridization to
GeneChip arrayHela cells
B
Fold Change  Description 
2.966 dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 2 
2.897 ADP-ribosylation factor-like 6 
2.713 RAB27A, member RAS oncogene family 
2.661 interleukin enhancer binding factor 3, 90kDa 
2.659 dudulin 2 
2.633 talin 1 
2.468 tissue factor pathway inhibitor 2 
2.188 growth differentiation factor 11 
0.488 vesicle-associated membrane protein 3 (cellubrevin) 
0.487 Rap guanine nucleotide exchange factor (GEF) 2 
0.486 follistatin 
0.475 caspase 9, apoptosis-related cysteine protease 
0.471 Bcl-3 (B-cell lymphoma associated protein) 
0.471 leucine zipper transcription factor-like 1 
0.435 transmembrane protein 2 
0.493 caspase 1, cysteine protease (interleukin 1, beta, convertase) 
0.425 inhibitor of DNA binding 2, dominant negative HLH protein 
0.416 glutamine-fructose-6-phosphate transaminase 1 
0.392 leucine zipper transcription factor-like 1 
0.332 transmembrane 4 superfamily member 3 
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Figure 2.2: IKK knock-down by Si-RNA reduced Bcl3 gene expression: Microarray result 
was validated in an independent experiment.  IKK is knocked-down  with different amount 
of siRNA transfections. Reduction Bcl-3 message level is well correlated with the amount of 
IKKe knock-down as measured by qRT-PCR (Fig. 2.2A). 16 and 24 represents the amount of 
transfection reagent (in µl) used. In addition to message level, IKK knock-down 
significantly reduced Bcl-3 protein level in HeLa cells.  Total cell lysates from different 
IKK si-RNA and the negative control (NC) si-RNA treated samples were prepared after 72 
hrs of si-RNA treatments. Different si-RNA against IKK has been used and we could only 
knock-down IKK effectively with product si-RNA ID number 919 from Ambion (Figure 
2.2B). Exogenously expressed WT IKK but not kinase mutant form (IKK KM) induce Bcl-
3 gene expression. Importantly, expression of IB super repressor (SR) inhibits IKK
induced Bcl-3 gene expression. p65 expression as well as TNF treatments induces 
significant Bcl-3 gene expression Fig. 2.2C). WT IKK but not its kinase mutant form 
activate luciferase promoter that has Bcl-3 promoter as well as an NFB responsive intronic 
enhancer (p11 E3+4 luciferase construct). These results suggest that IKK regulate Bcl-3 
gene expression in a NF-B dependent manner (Fig. 2.2D). WT IKK can induce cyclin D1 
(Fig. 2.2E) gene expression as well. Interestingly kinase mutant IKK (KM) reduces the 
basal level of Bcl-3 and cyclin D1 gene expression which suggest that kinase activity of 
IKK is important for its function. Vector control, IKK and IKK KM, IB SR and p65 
expression vectors were transiently expressed in HEK293T cells 
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Figure 2.2 
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Figure 2.3: Basal level as well cytokine induced level of Bcl-3 gene expression is defective in  
IKK KO MEF cells: RNA was isolated from WT MEF as well as IKK deficient MEF cell 
under  normal growing conditions. Bcl-3 gene expression is significantly low at the basal 
level in IKK deficient MEF cell line compared to WT MEF cells as measured by qRT-PCR 
(Fig. 2.3A). In order to explore inducible regulation of Bcl-3, WT MEFs as well as IKK
deficient MEFs were treated with LPS for indicated times, and Bcl-3 message level was 
quantified with qRT-PCR. IKK deficient cells have significantly low level of total Bcl-3 
message level upon LPS induction (Fig. 2.3B). Although there is some induction of Bcl-3 in 
IKK deficient cells, compared to WT cells this induction is significantly less. Bcl-3 protein 
level is also defective in IKK deficient cells. There is a detectable Bcl-3 gene expression 6 
hours after LPS induction, however, this can not be detected in IKK deficient cells (Fig. 
3C).  
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Figure 2.4: IKK and IKK independent, but NF-B p65 dependent Bcl-3 gene expression: 
MEF cells that are p65 knock-out (KO), and IKK and IKK double knock-out (DKO) were 
grown in 6-well plate and treated 10ng/ml TNF for indicated time points. p65 deficient 
MEFs display significantly less Bcl-3 gene expression at the basal level  and there seems to 
be no induction of Bcl-3 in p65 deficient cells upon TNF treatment for over 7 hr period 
compared to WT MEF cells  as measured by qRT-PCR (Fig. 2.4A). Interestingly, there is no 
significant difference in the level of Bcl-3 gene expression in IKK/ DKO MEFs and WT 
MEFs both basal and inducible levels seem to be comparably if not more in DKO cells (Fig. 
2.4B).  
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Figure 2.4 
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Figure 2.5: IKK and IKK independent phosphorylation of p65 by IKK: IKK and p65 
was exogenously expressed in IKK and IKK double knock-out MEFs grown under normal 
conditions in 6-well plate. Significant p65 phosphorylation at Ser 536 position is observed in 
the lane 6, where IKK and p65 is together (Fig. 2.5). It is important to note that TNF 
induced p65 phosphorylation is significantly reduced in IKK/ DKO cells compared to WT 
cells (Fig 5, compare lane 2 and lane 4). However, when the film is overexposed we can 
detect some inducible phosphorylation in DKO cells as well (data not shown). The fact that 
IKK can phosphorylate p65 in the absence of IKK and IKK suggest that IKK function 
independent of IKK/ at least in terms of p65 phosphorylation.  
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Figure 2.5 
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Figure 2.6: Bcl-3 over expressing cells proliferate more efficiently: MCF-7 cells and the 
same cell line with stably transfected Bcl-3 gene have been utilized. The same numbers of 
cells were plated in 4 96-well plates. Every 24 hr, cell proliferation was measured by MTT 
cell proliferation assay over a period of 4 days. Bcl-3 expressing cells (MCF-7B) proliferate 
more efficiently than the parental cells (MCF-7) (Fig 2.6). These results suggest that Bcl-3 is 
potentially a mechanistic link between IKK and cell proliferation. 
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Figure 2.6 
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Figure 2.7: Bcl3 and IKK overexpression in human HCC tumor samples: RNA and proteins 
from different samples of Human Hepato Cellular Carcinoma (HCC) tumors and adjacent 
tissue sections were prepared. Bcl-3 message level as well as IKK message level and protein 
levels have been quantified in different human tumor samples by qRT-PCR and western blot 
respectively both in adjacent tissue (A) and in Tumor section (T). There is significant Bcl-3 
overexpression in tumor samples 2, 3 and 4 specifically in tumor section compared to 
adjacent tissue. (A= adjacent tissue, T= tumor) (Fig. 2.7A). In line with this, there is also 
significant IKK overexpression in these samples as well as in sample # 1 (Fig. 2.7B). IKKQ
is overexpressed in almost all of the tumor samples at the protein level (Fig 2.7C). Over all, 
there is high correlation between IKK overexpression and Bcl-3 overexpression in 
specifically tumor section compared to adjacent tissue. 
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Materials and methods
Reagents: All cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM), 
complemented with 10% fetal calf serum (FCS), 100 units/ml penicillin, 100 Xg/ml 
streptomycin. An antibody to IKK>, Bcl-3 and to  phospho p65 Ser 536  was obtained from 
Cell Signaling.  Antibodies to I-tubulin, GAPDH and to I3BM were obtained from Santa 
Cruz. LPS (L6529, Sigma) was used at a final concentration of 1 µg/ml. Flag antibody (M2) 
was purchased from Sigma  rhTNF-M (Promega) was used at a final concentration of 10 
ng/ml.  Effectene transfection reagent obtained from Qiagen was used according to the 
manufacturer’s protocol. Generation of MCF-7B cells stably expressing Bcl-3 gene was 
previously described [84]. Wild type and kinase mutant forms of Flag-tagged IKK> (IKK>
K38A) have been described previously [27]. p11 E3+4 luciferase construct is described in 
[86] and was a kind gift of Dr. McKeithan.  
 
Transient Transfections: For transient transfections, the indicated cell lines were seeded in 6-
well plates at 30-50 % density and transfected the next day with the indicated expression 
vectors for 48 hrs using Effectene (Qiagen) transfection reagent according to the 
manufacturer’s instruction.  The total amount of transfected DNA (500 ng DNA) in each well 
was adjusted by adding empty plasmid vector (pcDNA3.1).  
 
Western Blot: After stimulation, cultured cells were lysed on ice for 5 min in RIPA lyses 
buffer with freshly added protease and phosphatase inhibitor cocktails.  Lysates were cleared 
by centrifugation at 4 °C for 15 min at 13,000 g. The amount of total protein was measured 
and equal amounts (20 µg) were fractionated by NuPAGE Novex 4-12% Bis Tris gels 
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(Invitrogen) and electro-transferred to polyvinylidene difluoride membranes.  Membranes 
were blotted with the indicated antibodies, and proteins were detected using an enhanced 
chemiluminescence detection system (Amersham Biosciences, Freiburg, Germany). 
 
Si-RNA transfection: IKK> mRNA was knocked down with the IKKe targeted si-RNAs from 
Ambion (IKKe Si-RNA ID # 918, 919, 9120) and from Dharmacon Company (IKKe targeted 
ON-TARGETplus siRNA and  Standard siGENOME siRNA). Dharmafect 1 transfection 
reagent was used for all si-RNA transfections. Lysate preparation and westerns were 
performed as described.  
 
Real-time PCR: Cells were plated in 100-mm dishes. Treated or untreated cells according to 
the proposed experiments were washed in PBS and lysed in Trizol Reagent (Invitrogen),  and 
RNA was collected following the manufacturer’s protocol.  cDNA was generated using the 
Superscript II Reverse Transcriptase kit (Invitrogen), and quantitative PCR was performed on 
an  ABI Prism 7000 (Applied Biosystems) using gene-specific TAQman primer/probe sets 
(Applied Biosystems). 
Cell proliferation, MTT assay: Cell proliferation assay has been performed as described by 
TACS MTT assay kit (R&D systems).  First, the optimal cell number, which was 1x104 for 
Hela cells in our system, has been determined. After transfection, equal number of cells has 
been seeded in 96 well plate for indicated times. 10 µl of MTT reagent was added to each 
well including the blank wells, and incubated for 4-5 hrs at 37 0C. Then 100 µl of detergent 
reagent was added, incubated for at least 12 hr at 37 0C and absorbances at 570 nm were 
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measured with reference wavelength of 650 nm.  
 
Microarray Method: 7 µg of total RNA was used to synthesize cDNA.  A custom cDNA kit 
from Life Technologies was used with a T7-(dT)24 primer for this reaction.  Biotinylated 
cRNA was then generated from the cDNA reaction using the BioArray High Yield RNA 
Transcript Kit.  The cRNA was then fragmented in fragmentation buffer (5X fragmentation 
buffer: 200mM Tris-acetate, pH8.1, 500mM KOAc, 150mM MgOAc) at 94oC for 35 minutes 
before the chip hybridization.  15 µg of fragmented cRNA was then added to a hybridization 
cocktail (0.05 µg/µl fragmented cRNA, 50 pM control oligonucleotide B2, BioB, BioC,
BioD, and cre hybridization controls, 0.1 mg/ml herring sperm DNA, 0.5 mg/ml acetylated 
BSA, 100mM MES, 1M [Na+], 20mM EDTA, 0.01% Tween 20).  10 µg of cRNA was used 
for hybridization.  Arrays were hybridized for 16 hours at 45oC in the GeneChip 
Hybridization Oven 640.  The arrays were washed and stained with R-phycoerythrin 
streptavidin in the GeneChip Fluidics Station 400.  After this, the arrays were scanned with 
the Hewlett Packard GeneArray Scanner.  Affymetrix GeneChip Microarray Suite 5.0 
software was used for washing, scanning, and basic analysis.  Sample quality was assessed 
by examination of 3’ to 5’ intensity ratios of certain genes. 
 
SUMMARY AND ADDITIONAL DIRECTIONS 
 
NF-B is one of the most extensively studied transcription factor since its initial 
discovery more than 20 years ago. Intensive research has demonstrated that NF-B is the 
central mediator of inflammatory responses and immune functions. Moreover, extensive 
research on NF-B has also demonstrated that this transcription factor can, in most cases, 
protects transformed cells from apoptosis and therefore participate in the onset or progression 
of many human cancers. NF-B comprises a family of dimeric transcription factors that 
regulate diverse gene expression programs consisting of hundreds of genes. A family of 
inhibitor of B (IB) proteins controls NF-B DNA-binding activity and nuclear 
localization. IB protein metabolism is intricately regulated through stimulus-induced 
phosphorylation, degradation and feedback re-synthesis, which allows for dynamic control of 
NF-B activity. This network of interactions is called NF-B signaling module. One of the 
most important components of this module is kinases that regulate NF-B activity at several 
points including IB phosphorylation and subsequent degradation. A large kinase complex 
responsible for IB phosphorylation and subsequent degradation was initially partially 
identified in unstimulated  HeLa cells and was later found to be activated in cells treated with 
TNF [8, 9]. Subsequently several groups identified two highly related kinases named  
IKK (IKK1) and IKK (IKK2) as the main kinase components of this kinase complex [10-
12]. Both of these kinases have been shown to have specificity for serine residues in the
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destruction box of IB protein and can directly phosphorylate S32 and S36 residues [10]. In 
addition to IKK and IKK, a third non-catalytic, structural component called 
IKK (NEMO) was also identified to be the essential component of the IKK complex [13-
15]. Please refer to [10] for more extensive and detailed review about IKK complex. 
 
Based on a number of observations, it was assumed that virtually all inducers of NF-
3B lead to the activation of a single classical IKKM/I/N complex. However, recent studies 
demonstrated the existence of distinct IKK complexes that do not contain IKKM, I, or N [26].  
One of these complexes was described as a PMA-inducible I3B kinase complex, with a 
critical component being an IKK-related kinase designated IKK>Q [27], which is identical to a 
kinase named IKK-i identified via its induction downstream of LPS-induced signaling [19]. 
IKK> in turn is closely related to another recently discovered IKK-related kinase designated 
as TBK1 (TANK-Binding Kinase 1) [28] or NAK (NF-3B Activating Kinase) [29].  TBK1, 
which is highly homologous to IKK>, binds to TANK and TRAF and may form an 
alternative IKK complex consisting of IKK> and TBK1 [28]. There is significant sequence 
similarity between IKK and TBK1 (~66 %) and they share a significant similarity in their 
kinase domains with IKK and IKK (Figure 1.1). 
 
Here, we have investigated the role of IKK in NF-B activity. Our research has 
shown that IKK is expressed in a variety of cancer cell lines. Based on this, we have 
investigated a role for IKK> as related to constitutive, cancer-associated NF-B activity. Our 
experiments reveal an important role for IKK in controlling the activation of Ser-536 
phosphorylation of the RelA/p65 subunit and functional NF-B activity in several cancer cell 
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lines and in 293T cells. Additionally, we have investigated IKK regulated gene expression 
at genome wide level and have identified Bcl-3 and Caspase 1 as critical IKK target genes.  
 
Here we show that several cancer cell lines, along with the SV40 large T-
immortalized 293 cell line, exhibit relatively high levels of expression of IKK. This is 
interesting, as IKK is normally considered a kinase that is induced quantitatively by LPS or 
cytokines. We have investigated a potential role for IKK and TBK1, kinases homologous to 
the catalytically active IKK and IKK subunits, in controlling NF-B activity, with the 
focus being phosphorylation of p65 at the Ser-536 position. Experiments were initiated to 
study IKK> and TBK1 induced NF-B-dependent promoter activation. 
 
In agreement with previous results [31, 32], IKK> and TBK1, but not their kinase 
mutant forms, strongly activate NF-3B regulated reporter constructs. It is important to note 
that, unlike the 3X-3B promoter, the IFN-I promoter is a complex promoter regulated by 
coordinate actions of NF-3B and other transcription factors, therefore it is not considered to 
be regulated exclusively by NF-3B. To confirm our reporter assays, gel shift assays have 
been performed. As expected, IKK> and TBK1 induced significant NF-3B DNA binding 
activity. Super shift assays identified p65 and p50 as main subunits of NF-3B complex.  
Recent studies have shown that post-translational modification of NF-3B subunits, such as 
p65 phosphorylation; contribute significantly to NF-3B activation.  Phosphorylation of p65 at 
Ser-536 is proposed to be a key modification that potentiates p65 transactivation function, 
and hence NF-3B activation ability [41, 72, 78]. 
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Recently, it has been reported that overexpression of IKK> or TBK1 together with 
p65, leads to the phosphorylation of ectopically expressed p65 at Ser-536 [40], however, this 
group has not analyzed the endogenous phosphorylation at Ser-536 of p65.  Our results 
clearly support the hypothesis that the kinase activity of IKK> and TBK1 may significantly 
contribute to the constitutive level of S536 phosphorylation of p65.  We have also observed 
that IKK> induces its own expression, which has been shown to be regulated by NF-3B.  This 
data indicates that ectopically expressed IKK> induces p65 phosphorylation, NF-3B
activation and NF-3B dependent gene expression. It is also raises the possibility that 
IKK functions in an autoregulatory loop, leading to its own expression.  
 
It was interesting to observe that IKK> deficient cells show a normal pattern of 
cytokine inducible phosphorylation of p65 and I3BM degradation when compared to WT 
MEFs.  We have tested a series of well known NF-3B inducers (IL-1I, LPS, PMA) that are 
known to activate NF-3B by utilizing different signaling pathways.  Compared to WT MEFs, 
IKK> null cells (and DKO MEFs for both IKK> and TBK1) allowed inducible RelA/p65 
phosphorylation to the same extent. Why is there no defect in inducible Ser-536 
phosphorylation of p65 in IKK> deficient cells?  The first plausible explanation to this 
question is that the classical IKK signalsome complex is still intact in IKK> deficient cells.  
Therefore, this complex likely compensates for the loss of IKK>. Secondly, there are other 
known and unknown kinases, in addition to IKK complex, that have been claimed to mediate 
Ser-536 phosphorylation of p65 [41, 80, 81] and in the same way, they may still induce 
phosphorylation in IKK> deficient cells.  The third explanation to this question is that IKK>
and TBK1 are not involved in cytokine induced p65 phosphorylation, but rather they are 
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involved in basal/constitutive level of p65 phosphorylation. In one set of experiments, this 
possibility has been investigated.  Since MEF cells have low levels of basal p65 
phosphorylation and low levels of IKK>, the potential that IKK> and TBK1 might be 
involved in constitutive p65 phosphorylation has been investigated in HeLa and HEK 293T 
cells that demonstrate higher levels of IKK> and constitutive p65 phosphorylation at Ser-536 
position.  IKK> was knocked down by plasmid based shRNA technology in both HeLa cells 
and HEK 293T cells.  Importantly, shRNA transfection leads to sustained knock down of 
IKK> and more importantly, reduction in the IKK> level is well correlated with significant 
reduction in the basal level of Ser-536 phosphorylation (Fig. 6), whereas in vector control 
transfected cells there is no change in IKK> level and Ser-536 phosphorylation of p65.  
Interestingly knock-down of TBK1 did not reduce the basal level of p65 phosphorylation.  
Surprisingly this data suggests that TBK1 and IKK> are not entirely orthologues at least in 
controlling basal phosphorylation of p65.  As suggested earlier [35], IKK> and TBK1 might 
not be redundant in every signaling pathway that they effect. Thus the data presented here 
clearly show that IKK> does not mediate cytokine-induced p65 phosphorylation at the Ser-
536 position but has a significant role in basal and constitutive phosphorylation of p65 at 
least in certain cancer cells and in 293T cells.  Basal p65 phosphorylation is well correlated 
with constitutive NF-3B activity, which has been implicated in the pathogenesis of many 
diseases including cancer. The first evidence to our conclusion that IKK> mediates 
constitutive NF-3B activity came from a recent report published while this paper was in 
preparation [45].  In that study, Eddy et al., provided evidences that IKK> contributes to the 
pathogenesis of breast cancer.  Expression of a kinase inactive form of IKK blocked breast 
cancer cell colony formation. The results presented in that manuscript are consistent with the 
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findings presented here. We have shown that IKK> contributes to the basal/constitutive p65 
phosphorylation and NF-3B activity as measured by EMSA and NF-3B driven luciferase 
promoter activity. Furthermore, we have also shown that knock-down of IKK> or 
overexpression of mutated version of p65 (S536A) negatively effects the cell proliferation. 
These findings indicate an important role of IKK> and p65 phosphorylation in cancer cell 
proliferation.  
 
There have been reports suggesting that IKK> and TBK1 may function as I3B kinase 
kinases [29, 82]. Therefore they might function upstream of the classical IKK complex 
(IKKM/I/N).  So we questioned if the phosphorylation of p65 at Ser-536 is a direct or indirect 
effect of IKK>/TBK1.  In other words, IKK> and TBK1 might have activated classical IKKs, 
which then lead to the phosphorylation of p65.  In order to test this, we tried to detect 
activation of IKKI and IKKM by probing the same blots in Fig. 4 with commercially 
available, phospho-IKKM/I antibodies, however we could not detect any phosphorylation 
(data not shown). Although we cannot rule out that IKK or TBK1 might function as I3B
kinase kinases, our data support a model where these two kinases are direct effectors of p65 
activation. There is evidence in the literature supporting this model.  First of all, it has been 
clearly shown that stimulus-coupled I3B degradation and p65 nuclear translocation and DNA 
binding activity of NF-3B is normal in IKK> and TBK1 deficient cells despite the fact that 
there is impaired NF-3B-dependent gene transcription [35, 36, 39]  This evidence supports 
the fact that the activity of IKKM and IKKI is normal in IKK> or TBK1 deficient cells, since 
there is normal I3B degradation, normal p65 nuclear translocation and normal DNA binding 
activity. We believe that our data, together with these findings, emphasize the RelA/p65 as 
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the physiological target of IKK> and TBK1 under basal growth situations, at least in certain 
cells. If IKK> and TBK1 were upstream of classical IKKs, one would expect a deficiency in 
one of the above processes which are tightly regulated by IKKM and I.
Furthermore, we have focused our research on understanding the downstream target 
genes whose expression is regulated by IKK. Interestingly Bcl-3 was identified as one of 
those genes that is regulated by IKK and display similar phenotype as IKK in terms of cell 
proliferation and survival. There is ample evidence in the literature implicating Bcl-3 in cell
cycle, immunity and inflammation; however, currently there is an unmet requirement of
identifying the upstream signaling mechanism and effectors of regulation Bcl-3 gene
expression. Here, we report that that IKK is important regulator of Bcl-3 gene expression.
Identification through microarray analysis of genes that are affected by IKK knock-down, 
and subsequent validation biochemical experiments suggested that Bcl-3 gene expression is 
regulated by IKK in a NF-B dependent manner. In addition, our data suggest that
regulation of Bcl-3 by IKK is potentially the mechanistic link and the main mediator of
IKK induced cell survival/proliferation.
Upstream effectors and transcription factors regulating Bcl-3 gene expression have
not been fully investigated. One study reported that Bcl-3 expression is upregulated
following IL-4 deprivation under the control of AP1 and AP1-like transcription factors [68].
However, Bcl-3 expression was also shown to be regulated by NF-B transcription factor
through an intronic enhancer in T lymphocytes [86]. Whether Bcl-3 is an NF-B or AP1
dependent genes, or if each transcription factors regulates differentially under different
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circumstances remains to be identified. Our data presented here suggest that NF-B p65 is an
important mediator of Bcl-3 gene expression. In p65 KO MEFs, there is significant reduction
in the basal level of Bcl-3 mRNA and it can not be induced upon cytokine stimulation.
Interestingly, IKK/ which are the main NF-B kinases did not seem to be involved in Bcl-
3 gene expression. This data suggested the activation of p65 by a third kinase other than
IKK/. Recently, several groups including us reported that IKK is an important p65 kinase
that phosphorylate at Ser 536 position and contribute to NF-B regulated gene expression
and cell proliferation [40, 44, 45]. Previously, IKK and TBK1 were suggested to act as
upstream kinases of IKK complex [26]. Whether IKK induces p65 phosphorylation directly
or act as an upstream kinase of IKK is currently unknown. We present evidence here that this
phosphorylation is a direct effect. First of all, IKK can induce p65 phosphorylation in
IKK/ double knock-out MEF cells (Fig. 5). Furthermore, p65 can be co-
immunoprecipitated with IKK (Data not shown). In addition to this, from the previous 
research in the literature, we know that stimulus-coupled I3B degradation and p65 nuclear 
translocation and DNA binding activity of NF-3B is normal in IKK> and TBK1 deficient 
cells despite the fact that there is impaired NF-3B-dependent gene transcription [35, 36, 39, 
44]  This evidence supports the fact that the activity of IKKM and IKKI is normal in IKK> or 
TBK1 deficient cells, since there is normal I3B degradation, normal p65 nuclear 
translocation and normal DNA binding activity.  Although we cannot rule out the possibility 
IKK might function as I-3B kinase kinase, our data support a model where IKK is a direct 
mediator of p65 activation and is working in parallel with classical IKK complex 
differentially under different circumstances.  
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Bcl-3 has been implicated in many crucial physiological events such as cell 
proliferation, immune, inflammation and cancer progression. We have also observed that 
cells with a stable Bcl-3 expression priloferate more efficiently than parental cell lines.  Bcl-3 
induced Cyclin D1 upregulation and inhibition of apoptosis are probably the two main 
mechanisms that accounts for better survival and proliferation in Bcl-3 expressing cells. Bcl-
3 upregulation has been observed in many cancer types [85, 89, 90] and hepatocellular 
carcinomas and pancreatic cancers (B. O’Neil, unpubl.). Interestingly most of these cancers 
have elevated basal NF-B activity and we have reported that IKK is the major player of 
cancer cell associated NF-B activity. We have observed strong correlation between IKK
expression and bcl-3 gene expression specifically in the tumor section of hepatocellular 
carcinomas samples compared to the adjacent tissue section (Fig. 7), which suggests that 
IKKe Qis driving Bcl-3 gene expression in tumor settings. Previous research and the data 
presented here so far indicate that IKK is an important mediator of constitutive NF-B
activity in cancer cells and Bcl-3 is one of the important target gene that is upregulated 
downstream of IKK induced NF-B activity. 
 
In addition to Bcl-3, our data suggest Caspase 1 as another IKK regulated gene. 
Caspase 1 is an important component of the inflammasome complex and has been shown to 
mediate chemo resistance in pancreatic carcinoma cell lines by autocrine production of 
interleukin 1beta (IL-1) that confers constitutive nuclear factor kappaB activity [91]. 
Experiments are further testing the role of Caspase 1 involvement in cell survival and growth 
downstream of IKK. How IKK regulate the expression of its target genes is not clearly 
understood, however our results suggest that p65 phosphorylation at ser 536 position is an 
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important step. In support of our data, IKK has recently been shown  to interact with p52 
and promote transactivation via p65 activation [42]. We cannot rule out the possibility that 
IKK has other roles in other NF-B activating pathways as the significant of IKK
involvement is recently being appreciated. One study, for example, demonstrated that TBK1 
and IKK directly phosphorylate the C-terminal domain of cRel in vitro and in vivo and 
regulate nuclear accumulation of cRel, independently of the classical IkappaB/IKK pathway 
[32]. While this work was in preparation, Boehm at al., published a paper in the most recent 
issue of Cell that clearly identified IKK as a Breast Cancer Oncogene by using Integrative 
Genomic Approaches such as overexpression and siRNA screening as well as comparative 
genomics analysis [43]. In line with out published studies, they also showed that in many 
breast cancer cell lines as well as breast cancer ca2rcinomas, IKK is overexpressed and this 
overexpression is driving NF-B activity which provide prosurvival signal in cancer setting. 
 
To summarize, we have provided evidence that IKK, and not TBK1, controls the 
constitutive NF-B activity in certain cancer cells and in 293T cells. This evidence is 
supported by siRNA experiments and by associated reporter studies. It is presently unclear 
whether IKK functions separately from the classic IKK complex, or through distinct 
regulatory pathways. It is also unclear whether IKK is the kinase that directly controls Ser-
536 p65 phosphorylation. Nevertheless, the data indicate a potentially important role for 
IKK in controlling at least part of the constitutive NF-B activity generated in certain 
cancer cells, with subsequent downstream effects on cancer cell proliferation. Interestingly, 
IKK is one of the NF-B regulated genes therefore there is positive regulatory loop between 
IKK expression and NF-B activity. Based on our current understanding of IKK and NF-
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B activity, we have developed a model as depicted in Figure A. Furthermore, we have also 
identified that Bcl-3 is an important IKK regulated gene downstream of NF-B activity. 
This finding is interesting as we know that Bcl-3 is an important mediator of cell cycle and 
cancer progression and this effect may at least partly come from Bcl-3 regulation of Cyclin 
D1. Over all these result suggest that Bcl-3 might be the mechanistic link between IKK
induced cell survival and proliferation. Moreover, Caspase1, which has essential role in IL-
1B processing and maturation, has also been identified as an IKK regulated gene and the 
physiological consequences of this regulation is yet to be understood. 
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Figure A: IKK induced cancer cell associated basal NF-B activity. IKKe leads to 
constitutive NFB activation in cancer associated settings. Without any outside stimuli, or 
yet to be identified activation signal, IKK and potentially other unknown kinases induces 
p65 phosphorylation at ser 536 position and hence activate NF-B independent of classical 
IKK complex which then activate genes required for cell survival and proliferation including 
Bcl-3 and IKKe itself. 
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